



IB/2004/04335



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 12 JAN 2005

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.


In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)



Signed

*Andrew*

Dated

17 December 2004



**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



1. Your reference	P036148GB:HRG		
2. Patent application number (The Patent Office will fill in this part)	05 DEC 2003 ✓ 0328261.3 ✓		
3. Full name, address and postcode of the or of each applicant (underline all surnames)	University of Groningen Antonius Deusinglaan 1 9713 AV Groningen The Netherlands		
07681299 002 Patents ADP number (if you know it)	(For further applicants please see continuation sheet)		
If the applicant is a corporate body, give the country/state of its incorporation	The Netherlands		
4. Title of the invention	IMPROVED CYTOKINE DESIGN		
5. Name of your agent (if you have one)	Carpmaels & Ransford		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	43-45 Bloomsbury Square London WC1A 2RA		
Patents ADP number (if you know it)	83001 ✓		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:	Yes		
a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body			
See note (d))			

# Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	1
Description	46
Claim(s)	4
Abstract	
Drawing(s)	13

+ 13 SN

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

*Carpmaels & Ransford*  
Carpmaels & Ransford

5th December 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr. Hugh Goodfellow

020-7242 8692

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

European Molecular Biology Laboratory  
Postfach 102209  
69012 Heidelberg  
Germany

07901325001

National University of Ireland, Galway  
University Road  
Galway City  
Ireland

08768269001

### Improved cytokine design

The present invention relates to novel methods for the design of proteins, in particular, cytokines. These methods allow the stabilisation of such cytokines, as well as modification of their selectivity/specificity for their cognate receptors. The invention also relates to various modified proteins that have been designed by the methods of the invention.

Cytokines are a family of growth factors secreted primarily from leukocytes, and are messenger proteins that act as potent regulators capable of effecting cellular processes at sub-nanomolar concentrations. Their size allows cytokines to be quickly transported around the body and degraded when required. Their role in controlling a wide range of cellular functions, especially the immune response and cell growth has been revealed by extensive research over the last twenty years (Boppana, S.B (1996) *Indian. J. Pediatr.* 63(4):447-52). These roles include immune response regulation (Nishihira, J. (1998) *Int. J. Mol. Med.* 2(1):17-28), inflammation (Kim, P.K. *et al* (2000) *Surg. Clin. North. Am.* 80(3):885-894), wound healing (Clark, R.A. (1991) *J. Cell Biochem.* 46(1):1-2), embryogenesis and development, and apoptosis (Flad, H.D. *et al* (1999) *Pathobiology.* 67(5-6):291-293).

Clinical use of cytokines to date has focused on their role as regulators of the immune system (Rodriguez, F.H. *et al* (2000) *Curr. Pharm. Des.* 6(6):665-680) for instance in promoting a response against thyroid cancer (Schmutzler, C. *et al* (2000) 143(1):15-24). Their control of cell growth and differentiation has also made cytokines anti-cancer targets (Lazar-Molnar, E. *et al* (2000) *Cytokine.* 12(6):547-554; Gado, K. (2000) 24(4):195-209). Novel mutations in cytokines and cytokine receptors have been shown to confer disease resistance in some cases (van Deventer, S.J. *et al* (2000) *Intensive Care Med.* 26(Suppl 1):S98:S102). The creation of synthetic cytokines (muteins) in order to modulate activity and remove potential side effects has also been an important avenue of research (Shanafelt, A.B. *et al* (1998) 95(16):9454-9458).

Cytokine molecules have thus been shown to play a role in diverse physiological functions, many of which play a role in disease processes. Alteration of their activity is a means to alter the disease phenotype and as such, the identification of novel cytokine molecules is of significant scientific interest.

Of particular interest are ligands that belong to the Tumor Necrosis Factor ligand (TNF) family; these proteins are involved in a wide range of biological activities, ranging from cell proliferation to apoptosis.

Members of the TNF ligand family induce signalling pathways that lead to apoptosis or programmed cell death (PCD) through interaction with their cognate receptors. Ligand-bound receptors transmit the signal across the membrane by bringing their cytoplasmic portions into close

proximity, leading to the recruitment and activation of downstream effector proteins. Apoptosis is a process fundamental to the normal development and homeostasis of multicellular organisms. However, the impairment of apoptosis regulation is implicated in the pathogenesis of cancer and several chronic diseases, including acquired immunodeficiency syndrome (autoimmune disease and  
 5 AIDS) and neurodegenerative disorders (eg Parkinsons). Common examples are chronic transplant dysfunction, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD) and asthma. Molecules that mediate reversal of imbalance in signal transduction could be effective therapeutics in diseases.

Members of the TNF ligand family are also master conductors of immune function and immune  
 10 tolerance. There is a complex balance between immunostimulatory and immunoregulatory functions within this family that ensures appropriate immune responses. Genetic polymorphisms in the TNF ligand receptor family can result in deregulation of immune homeostasis. Such deregulation can lead to pathogenesis.

The TNF family of ligands interact with their cognate receptors to trigger several signalling  
 15 pathways that play key roles in regulatory and deleterious effects on immune tolerance, in addition to both protective and pathogenic effects on tissues (Rieux-Laucat *et al.*, 2003, Current Opinion in Immunology 15:325; Mackay and Ambrose, 2003, Cytokine and growth factor reviews, 14: 311; Mackay and Kalled, 2002, Current opinion in Immunology, 14: 783-790). Examples of such proteins include ligands such as RANKL, TRAIL, and APRIL, which are implicated in disease  
 20 conditions such as rheumatoid arthritis, autoimmune diabetes, systemic lupus erythematosus (SLE), Sjörger's syndrome, experimental autoimmune encephalomyelitis (EAE), inflammatory bowel disease (IBD), autoimmune lymphoproliferative syndrome (ALPS) and multiple sclerosis.

All monomeric subunits of TNF ligand family members consist of antiparallel  $\beta$ -sheets, organised in a jellyroll topology, and these subunits self associate in bell-shaped homotrimers, the bioactive  
 25 form of the ligand. Sequence homology is highest between the (aromatic) residues responsible for trimer formation. A trimer binds three subunits of a cognate receptor, each receptor subunit binding in the grooves between two adjacent monomer subunits. The ligands are type II transmembrane proteins, but the extracellular domain of some members can be proteolytically cleaved from the cell surface, yielding a bioactive soluble form of the ligand. Recent reviews of the TNF ligand family  
 30 are readily available (Locksley *et al.*, *Cell* 104, 487-501 (2001); Bodmer *et al.*, Trends Biochem. Sci. 27, 19-26 (2002)).

Knowledge of members of the TNF ligand family can also be applied to other signalling pathways triggered by ligand-receptor interaction within the same and other families.

Although naturally-occurring cytokines are of significant interest to the scientific community, the  
 35 properties of many of these molecules do not necessarily suit their application in a clinical setting.

- For example, the stability of a cytokine is important throughout the production process and for the shelf-life of the final product, as well as influencing the pharmacokinetic and -dynamic properties of the protein therapeutic (Marshall *et al.*, *Drug Discov. Today* 8, 212-221 (2003)). Several strategies are currently used to augment the thermal stability of proteins (Fersht, A. & Winter, G.
- 5 Protein engineering. *Trends Biochem. Sci.* 17, 292-295 (1992); Van den Burg *et al.*, *Curr. Opin. Biotechnol.* 13, 333-337 (2002)). Both rational (Pantoliano *et al.*, *Biochemistry* 26, 2077-2082 (1987); Van den Burg *et al.*, *Proc. Natl. Acad. Sci. U. S. A* 95, 2056-2060 (1998); Villegas *et al.*, *Fold. Des* 1, 29-34 (1996)) and directed evolution methods (Giver *et al.*, *Proc. Natl. Acad. Sci. U. S. A* 95, 12809-12813 (1998); Jung *et al.*, *J. Mol. Biol.* 294, 163-180 (1999)) have been
  - 10 successfully used to improve stability. A disadvantage of a rational approach is that one can design only a limited number of potentially improved variants. In contrast, directed evolution methods allow large numbers of variants to be generated and screened. However, suitable selection/screening procedures are required, which are often not available or are very labour intensive.
  - 15 More recently, computational redesign algorithms have been employed to enhance stability, amongst other properties, of proteins (DeGrado *et al.*, *Annu. Rev. Biochem.* 68, 779-819 (1999)). These methods combine computer design steps with *in silico* screening, permitting screening of a much larger sequence space than is experimentally possible with high-throughput techniques. Efficient algorithms are needed to search the vast sequence space and accurate scoring functions
  - 20 are required in order to rank the best designs (Dantas *et al.*, *J. Mol. Biol.* 332, 449-460 (2003)). Some limited success has been achieved for certain proteins – for example, computational redesign has recently been used to generate a hyper-thermophilic variant of streptococcal G $\beta$ 1 domain protein (Malakauskas, S.M. & Mayo, S.L. *Nat. Struct. Biol.* 5, 470-475 (1998)), to enhance the stability of the spectrin SH3 domain (Ventura *et al.*, *Nat. Struct. Biol.* 9, 485-493 (2002)) and to
  - 25 improve the (thermal) stability of the therapeutically interesting four helix bundle cytokines, granulocyte colony stimulation factor (G-CSF) and human growth hormone (hGH). However, the various shortcomings of these methods do not allow their widespread application.
- It would also be of great use were it possible to alter the selectivity/specificity of cytokines for their receptors. For example, certain members of the TNF ligand family bind more than one receptor or
- 30 bind decoy receptors which lack or have truncated intracellular domains. A specific example is the tumor necrosis factor-related apoptosis inducing ligand (TRAIL; TNFSF10) Wiley *et al.*, *Immunity* 3, 673-682 (1995); Pitti *et al.*, *J. Biol. Chem.* 271, 12687-12690 (1996)), which in its soluble form binds its receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2), in addition to its decoy receptors, DcR1 (TRAIL-R3), DcR2 (TRAIL-R4) and OPG. Receptors DR4 (TRAIL-R1) and DR5 (TRAIL-
  - 35 R2) contain the cytoplasmic Fas associated death domain (FADD), and binding of TRAIL to these receptors induces apoptosis. TRAIL also appears to be able to induce the proliferative NF- $\kappa$ B



pathway through Tumor necrosis factor receptor associated death domain (TRADD). Having selective inducers of DR4 (TRAIL-R1) and DR5 (TRAIL-R2) signalling is likely to be of great interest, due to the presumably different cross-linking requirements of both death receptors. Depending on the cross-linking, the signalling pathway could induce the proliferative or the apoptic pathway. DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4) do not contain a death domain or contain a truncated death domain, respectively. Binding to these receptors does not induce apoptosis; on the contrary, it may actually prevent apoptosis by sequestering available TRAIL. DcR2 (TRAIL-R4) however appears also be capable of inducing the NF- $\kappa$ B pathway. Unlike other apoptosis inducing TNF family members, TRAIL appears to be inactive against normal healthy tissue, therefore attracting great interest as a potential cancer therapeutic (Ashkenazi *et al.*, *J. Clin. Invest* 104, 155-162 (1999)). A recent significant publication has however shown that TRAIL-R3 is upregulated by p53 in breast tumour cell through use of the genotoxic drug, doxorubicin (Ruiz de Almodóvar *et al.*, 2003, Nov 17, Manuscript M311243200). This implies that efficacy of wild-type TRAIL may be diminished in anti-tumour therapy since it also binds the decoy receptors (that do not initiate apoptosis). Therefore, variants of TRAIL, that have altered selectivity/specificity could be direct to the pro-apoptotic receptors, DR4 (TRAIL-R1) or DR5 (TRAIL-R2) and would have ultimately improved application in cancer treatment.

The TNF ligand family members, such as TRAIL, APRIL, RANKL, BAFF, LIGHT, FasL and TNF- $\alpha$  all bind more than one receptor. At least six death-domain-containing receptors have now been identified — Fas, TNF receptor 1 (TNF-R1), death receptor 3 (DR3; also known as TRAMP, Wsl, APO-3 and LARD), the two receptors for TNF-related apoptosis-inducing ligand (TRAIL) TRAIL-R1/DR4 and TRAIL-R2/DR5, and DR6. Certain member of the TNF ligand family also bind decoy receptors which lack or have truncated death domains, such as, TRAIL, which binds its decoy receptors, DcR1, DcR2 and OPG. The accumulation of recent knowledge in this area, therefore, opens new avenues for therapeutic design. In this respect, selectivity of novel molecules is of primary importance to discern the specific role of the activation of different receptors and therefore the functional effects of ligand binding to several receptors, and the concomitant influence on the pathogenesis of the associated diseases related to signal activation.

Rational design permits only a relative small amount of variants to be designed. For molecular evolution/high throughput screening (HTS) methods, selection and screening methods have to be developed and large libraries of variants have to be screened. Especially for enhancement of stability there are relatively few examples of successful selection or screening methods.

Computational design methods known in the art have only been applied to improve the stability of relatively small monomeric molecules, not to improve the stability of larger multimeric molecules. Often these designs are focused on changing amino acids in the core of the molecule. Changing

residues in the core (repacking the core) does stabilise molecules to some extent, but can lead to a molten globule state.

Computational design methods have also been used in the art to alter selectivity, but again only for relatively small monomeric molecules, not to improve the selectivity for binding partners of larger multimeric molecules. Furthermore, crystal structure is currently indispensable.

One aspect of the present invention uses a combination of computational redesign algorithms and educated manual input to design proteins that are more stable than their wild-type counterparts.

A second aspect of the invention relates to the redesign of proteins to alter their selectivity for receptor.

## 10 Summary of the invention

According to a first aspect of the invention, there is provided a computer-implemented method for the stabilisation of a  $\beta$  sheet multimeric cytokine, comprising the step of:

mutating a residue in a monomer component of the multimeric cytokine protein so as to improve the free energy of the monomer or of the multimeric complex relative to the wild-type unmutated monomer component, wherein said mutated residue is non-conserved between homologous members of the cytokine family.

Variants of  $\beta$  sheet multimeric cytokines with enhanced stability have a number of advantages, including increased *in vivo* and *in vitro* half-lives, increased yields generated during protein expression, greater stability during purification and an extended shelf-life compared to their wild-type counterparts. Stable variants of these proteins can thus be used as protein therapeutics or diagnostics. The proteins have a relatively close resemblance to the wild-type structure and this reduce the risk of immunogenicity, particularly when compared to variants stabilised by fusion tags, one currently favoured method of stabilising proteins. They also have advantages when compared to agonistic or antagonistic antibodies. In contrast to antibodies, variants can be produced in *Escherichia coli* and the mode of signalling more closely resembles that used by the wild-type cytokine protein.

The term "multimeric cytokine" as used herein is meant to include all  $\beta$  sheet multimeric cytokines. Examples of such cytokines are presented in Table 6. Other examples will be known to those of skill in the art. A recent review on structure of TNF ligand family is available (Bodmer *et al.*, 2002. Trends Biochem. Sci. 27, 19).

One feature of  $\beta$  sheet multimeric cytokines is that they are composed of identical monomeric subunits or of different monomeric subunits. Methodologies could be applied to all cytokine protein families and more specifically to the members of the TNF ligand-receptor family. Other

examples of families of proteins embraced by the superfamily of cytokines include those classed as Beta-Trefoil, Beta-sandwich, EGF-like, and Cystine knot cytokines).

Of particular interest for the application of the methodology of the invention are the  $\beta$  sheet multimeric cytokines that are members of the tumor necrosis factor ligand family. Ligands belonging to this family are involved in a wide range of biological activities, ranging from cell proliferation to apoptosis, and they share similar structural characteristics. All monomeric subunits of these ligands consist of antiparallel  $\beta$ -sheets, organized in a jelly-roll topology, and these subunits self associate in bell-shaped homotrimers, the bioactive form of the ligand. A trimer binds three subunits of a cognate receptor, each receptor subunit binding in the grooves between two adjacent monomer subunits. The ligands are type II transmembrane proteins, but the extracellular domain of some members can be proteolytically cleaved from the cell surface, yielding a bioactive soluble form of the ligand.

It has been found advantageous to use alignment information in order to focus the design on non-conserved residue positions. This method of protein stabilisation focuses on these non-conserved residues on the premise that conserved residues are usually retained in a family for a good reason and it is probable that any mutation of a conserved residue will decrease protein stability. On the other hand, regions with high sequence variability are tolerant to mutation and it can be expected that variants that stabilize the protein can be found in these regions. There is less evolutionary pressure for these residues to have been retained among the family members.

The combined approach of the method therefore employs family alignment information and a computational design algorithm. This reduces the sequence space search for every position in the protein being studied and decreases the computing time and power necessary for the methodology.

Identification of non-conserved residues can be done using any one of a number of systems known to the person of skill in the art. Such an analysis can be done by eye, but is more easily achieved using a computer-implemented alignment algorithm, such as BLAST (Altschul *et al.* (1990) *J Mol Biol.*, 215(3): 403-10), FASTA (Pearson & Lipman, (1988) *Proc Natl Acad Sci USA*; 85(8): 2444-8) and, more preferably, PSI-BLAST (Altschul *et al.* (1997) *Nucleic Acids Res.*, 25(17): 3389-402), ClustalW (Thompson *et al.*, 1994, *NAR*, 22(22), 4673-4680) or the like. Assessment of whether or not a residue is conserved will be clear to the skilled reader and will depend on the number of related proteins that are aligned and the degree of relatedness amongst them. For example, if only two family members are aligned and these proteins share 50% identity, then the conserved residues are those that are shared between the two proteins at the same positions. On the other hand, if 20 proteins in the same family are aligned, it is most unlikely that the least alike of these proteins will possess homology as high as this. Preferably, then, in an alignment between the candidate for mutation and representative members of the protein family, a conserved residue is

one that is shared between at least 20 % of the family, preferably at least 30 %, preferably at least 40 %, preferably at least 50 %, and may be at least 60 %, preferably 70 % or more. For example, sequence homology in the Tumor Necrosis Factor ligand family is highest between the (aromatic) residues that are responsible for trimer formation; these residues are thus unsuitable candidates for mutation according to the methodology of the invention.

Once non-conserved residues are identified, the next step in the method requires an evaluation of which of these residues are candidates for mutation.

Preferred aspects of the methodology mutate non-conserved residues that occupy positions at the surface of the monomer component in the multimeric cytokine protein structure. By doing this, the multimeric structure is stabilised as a whole.

As used herein, the term "at the surface" means that the residue concerned in the monomer remains surface-exposed in the multimer complex. Such residues are solvent-exposed and thus hydrophilic in nature. Of course, surface-exposed residues will be present not only at the surface of each monomer, but will also be surface-exposed in the multimer complex. Knowledge of the position of a particular residue in the structure of a protein may come from knowledge of the structure itself, or may be derived by extrapolation from the position of the equivalent residue in the structure of a protein in the same family.

Another preferred aspect of the methodology is to mutate non-conserved residues near positions close to the interface between two monomer components of the multimeric cytokine protein structure. This has the effect of stabilising the multimeric structure of the protein through stabilisation of the inter-chain interfaces.

As used herein, the term "near positions close to the interface between two monomer components" means that the residue concerned in the monomer is close to or at the interface formed when two monomer components of a multimeric protein complex together. The residue must be near enough to this interface for its constituent atoms to influence monomer-monomer interactions, preferably in a positive way. For hydrophobic interactions the distance may be as close as the Van der Waals' radius of subject atoms. For hydrogen bonding the distance may be from 2.7 angstrom to 3.1 angstrom, for electrostatic interaction the distance may be from 1.4 angstrom up to 12 angstrom. Such influence may be effected through, for example, polar or hydrophobic solvation energies, van der Waals' interactions, H-bond energies, electrostatics, or backbone and side chain entropies.

For trimeric proteins, one preferred aspect of the methodology is to mutate residues that occupy positions along the central trimeric axis in the multimeric cytokine protein structure. This has the effect of stabilising the trimer.

As used herein, the term "residues along the central trimeric axis" means that the residue concerned in the monomer is close to or at the interface formed when three monomer components of a trimeric protein complex together. As described above, the residue must be near enough to this interface for its constituent atoms to influence the confluence of the three monomer components

5 into a trimeric complex.

Most preferably, a method according to the invention mutates residues in more than one of the classes referred to above, preferably in at least two of the classes and even more preferably in all three of these classes.

10 The methodology described here is, to the inventors' knowledge, the first time that a technique incorporating computational engineering has been applied to redesign a large (>100 amino acids) all- $\beta$ -sheet protein towards a more thermally stable variant.

Until recently, lack of protein structural information in relation to multimeric  $\beta$  sheet cytokines and their receptors made intervention on the level of signal transduction initiation (ligand-receptor interaction) unfeasible. Detailed crystal structural information is now available for many of these

15 cytokines, together with reliable homology models. Therefore, studies on protein-protein interaction and the elucidation of mechanisms of ligand-receptor interaction and activation are now possible. For example, the following TNF ligand family members have been crystallised, either in complexed or uncomplexed forms: Human BAFF, Blys (Liu Y. *et al.*, 2002 *Cell* 108(3):383-94; Oren DA. *et al.*, 2002 *Nat Struct Biol.*, 9(4):288-92.; Karpusas M. *et al.*, 2002 *J Mol Biol.*

20 315(5):1145-54.); human CD40L (Karpusas M. *et al.*, 2001, *Structure (Camb)*. Apr 4;9(4):321-9.); murine RANKL/TRANCE (Lam J. *et al.*, 2001 *J Clin Invest.* 108(7):971-9.); human TNF- $\alpha$  (Banner DW. *et al.*, 1993 *Cell*. 1993 May 7;73(3):431-45.; Eck MJ. *et al.*, 1992 *J Biol Chem.*, 267(4):2119-22.) human TRAIL (Mongkolsapaya J *et al.*, 1999 *Nat Struct Biol.* 6(11):1048-53., Cha SS. *et al.*, 1999, 2000 *Immunity*. 1999 Aug;11(2):253-61. 2000 *J Biol Chem*. 2000 Oct

25 6;275(40):31171-7.; Hymowitz SG. *et al.*, 1999 *Mol Cell*. 4(4):563-71), human TNF- $\alpha$  (Reed C. *et al.*, 1997 *Protein Eng.* 10(10):1101-7; Cha SS. *et al.*, 1998 *J Biol Chem*. 1998 Jan 23;273(4):2153-60; Naismith JH. *et al.*, 1996 *Structure*. 1996 Nov 15;4(11):1251-62., Naismith JH. *et al.*, 1995, *J Biol Chem*. 1995 Jun 2;270(22):13303-7. 1996 *J Mol Recognit*. 1996 Mar-Apr;9(2):113-7.; Carter PC. *et al.*, 2001 *Proc Natl Acad Sci U S A*, ;98(21):11879-84. Erratum in: *Proc Natl Acad Sci U S*

30 A 2001 Dec 18;98(26):15393.). Therefore, the amino acids that make up domains representing protein-protein interaction motifs between these ligands and their respective receptors are now known. Such interacting domains in the TNF family have an intrinsic propensity to initiate signalling pathways associated with the modulation of diseases such as cancer and chronic diseases such as autoimmune disease, and are starting points for drug design.

Visualisation of the structure of a candidate cytokine protein may be performed computationally using one or other of the many systems available for this task. Such systems are generally designed to import data describing a protein structure (such as a structure from the Protein Data Bank, the PDB) and convert this to a three-dimensional image. At present, the largest public depository of information relating to protein structure is the PDB database (<http://www.rcsb.org/pdb>), that now includes over 23,000 protein and nucleic acid structures, elucidated using methods of x-ray crystallography and nuclear magnetic resonance. Images of protein structure allow intimate analysis of the structure of a protein to evaluate the positions of each residue in the protein structure, and an evaluation of which residues participate in interactions with other moieties, such as a receptor or monomer partner.

For example, in the example described herein, the structure of the TRAIL protein is visualised using the template PDB structure 1DU3 (Cha *et al.*, *J. Biol. Chem.* 275, 31171-31177 (2000)). The crystal structure at 2.2 Å resolution contains the trimeric structure of human TRAIL in complex with the ectodomain of the DR5 (TRAIL-R2) receptor. In this case, the TRAIL monomer lacks an external, flexible loop (130-146), not involved in receptor binding or in monomer-monomer interaction. Accordingly, to complete the molecule, this loop was modelled using the structure of 1D4V (2.2 Å) (Mongkolsapaya *et al.*, *Nat. Struct. Biol.* 6, 1048-1053 (1999)), a monomeric TRAIL in complex with DR5 (TRAIL-R2) receptor, having the atomic coordinates of the loop. Finally, the TRAIL molecule was isolated by removing the receptor molecules from the PDB file.

Already, there are computer-implemented programs that allow the prediction of protein structure *ab initio*, or by inference from closely-related proteins of known structure. Accordingly, for the method of the invention, it is not strictly necessary for the structure of a candidate protein to be known. A significant amount of information can be gleaned by analogy from structures of related proteins; for example, TNF ligand family members show similar trimeric structures.

For example, for some  $\beta$  sheet multimeric cytokines, such as APRIL, there is no available structure of the complex with the receptor. However, there is generally structural information available for homologous ligands and receptors, which allows the complexes to be built by Homology Modelling. This is particularly true in those cases in which the sequence homology is higher than 40 % and insertions or deletions are not found in the binding region of ligand and receptor.

Visualisation of the isolated monomers, monomer-monomer interface and central core of the candidate protein will show the residues that are potential candidates for mutagenesis.

In the case of design for stability mutants, in order to filter out unsuitable residues for mutagenesis, any highly conserved hydrophobic residues should be discarded from the list of potential candidates for mutagenesis. In addition, residues involved in receptor binding should be discarded in the case of design for stability mutants. These residues cannot be mutated without disrupting

interactions with the receptor. The sequence space search for every position may preferably be simplified, by checking the naturally occurring amino acids in a multiple sequence alignment of proteins belonging to the family of interest, thus decreasing the computing time, and subsequently focusing on non-conserved residues.

- 5 Preferably, in conjunction with a visualisation tool, a protein design algorithm is used to facilitate the identification of candidate residues for mutation. Examples of suitable algorithm include the "WHATIF" program (Vriend, (1990), J Mol Graph 8(1), 52-6, 29) or more sophisticated programs such as the algorithm "PERLA" (protein engineering rotamer library algorithm) (Fisinger S, Serrano L, Lacroix E. Protein Sci. 2001 Apr;10(4):809-18). The latter, based on a rotamer library
- 10 search, allows a combinatorial exploration at different positions simultaneously in the protein, and identifies the optimal sequence that improves a structural property of the protein (such as its stability). A detailed description of this algorithm is available elsewhere (Lacroix, E. Protein design: a computer based approach, Ph.D.thesis. (U. Libre de Bruxelles, 1999)) (<http://ProteinDesign.EMBL-Heidelberg.DE>) and its use has been previously described (Ventura *et al.*, Nat. Struct. Biol. 9, 485-493 (2002); Fisinger *et al.*, Protein Sci. 10, 809-818 (2001); Lopez *et al.*, J. Mol. Biol. 312, 229-246 (2001); Reina *et al.*, Nat. Struct. Biol. 9, 621-627 (2002)). Other
- 15 suitable algorithms include 3D Jigsaw and EasyPred.

Briefly, the PERLA algorithm performs strict inverse folding: a fixed backbone structure is decorated with amino acid side chains from a rotamer library. Relaxation of strain in the protein

20 structure is achieved via the generation of subrotamers. Most terms of the scoring function are balanced with respect to a reference state, to simulate the denatured protein. The side chain conformers are all weighted using the mean-field theory and finally candidate sequences with modelled structures (PDB coordinates) are produced.

In the case of a multimeric protein such as the TNF family ligand TRAIL, protein design with

25 PERLA requires the following steps.

Firstly, residues of a monomer that could establish specific interactions with the contiguous monomer must be identified and selected as described above.

Secondly, side chains that contact the residues that are candidates for mutation must be identified to allow side chain movements that are necessary to accommodate the new residues introduced by the

30 algorithm. PERLA automatically selects these residues based on a geometrical approach that takes  $C\alpha$ - $C\alpha$  distances and the angle between  $C\alpha$ - $C\beta$  vectors into consideration.

Thirdly, the algorithm places the amino acid repertoire at each position selected from a set of naturally occurring amino acids in a multiple sequence alignment of the TNF ligand family, and

eliminates from consideration those side-chain conformations and amino acids that are not compatible with the rest of the structure.

Fourthly, all possible pair-wise interactions are explored to eliminate those combinations that are less favourable. This energy evaluation is preferably carried computationally, for example using a force field algorithm such as the program FOLD-X (Guerois *et al.*, *J. Mol. Biol.* 320, 369-387 (2002)) or a modified version (Schymkowitz, J., Borg, J., Rousseau, F. & Serrano, L, "manuscript in preparation") of this program, available at (<http://fold-x.embl-heidelberg.de>). The force field module of FOLD-X evaluates the properties of the structure, such as its atomic contact map, the accessibility of its atoms and residues and the backbone dihedral angles, in addition to the H-bond network and electrostatic network of the protein. The contribution of water molecules making two or more H-bonds with the protein is also preferably taken into account. FOLD-X then proceeds to calculate all force field components: polar and hydrophobic solvation energies, van der Waals' interactions, van der Waals' clashes, H-bond energies, electrostatics, and backbone and side chain entropies.

Finally, an output of sequences and PDB coordinates corresponding to the best calculated solution (in terms of energy) is produced and may be ranked in terms of free energy, for instance, using FOLD-X.

The resultant data files (preferably PDB files or similar) containing the mutations should then be energy-minimized. One way of doing this is by using a program such as GROMOS 43B1 as implemented in Swiss-PdbViewer v3.7b2 (Guex & Peitsch; *Electrophoresis* 18, 2714-2723 (1997)), and evaluated by FOLD-X (<http://fold-x.embl-heidelberg.de>). The final energies of the models are then compared to the reference, wild-type structure and expressed as  $\Delta\Delta G$  (kcal mol<sup>-1</sup>).

Favourable mutations may of course be combined and evaluated in terms of free energy (kcal mol<sup>-1</sup>). Unfavourable combinations (e.g. high Van der Waals' clashes) should be eliminated.

If necessary, outputs of sequences and co-ordinates may subsequent to the design process be reintroduced in the design algorithm for a further round or rounds of design. 2nd, 3<sup>rd</sup>, 4<sup>th</sup>, 5<sup>th</sup> or more rounds of design may be used.

The above methodology facilitates the calculation of free energy, which must be improved by mutation of the monomer, relative to the free energy of wild-type unmutated monomer. By "free energy" is meant the free energy of folding. By "free energy of folding" is meant the difference in Gibbs energy (including enthalpic and entropic terms) between the protein in a folded or partially folded state and the protein in its fully denatured state. In calculating the free energy of folding, the calculation should take into account factors such as the accessibility of atoms, the existence of hydrogen bonds and the existence of electrostatic charges between atoms that are predicted to occur



in the folded structure, the van der Waals' interactions, the solvation, the main chain and side chain entropic effects being also taken into account. These atomic energetic calculations are then summed. This calculation should thus ideally take account of the nature of the stabilising interactions that compete with or favour the topological constraints that are inherent in a particular

- 5 protein folding pathway, taking sequence considerations into account when calculating the main chain, the side chain and the loop entropic costs and the favourable contributions to protein stability. Such a method thus should incorporate detailed energetic functions that effectively estimate the balance between topological constraints (entropic origin) on the one hand and interactions stabilising a fold, on the other.
- 10 The free energy of a particular protein may be assessed using any suitable method, as will be clear to the skilled reader. A number of suitable computer programs exist for the automated calculation of free energy; one preferred program is the FOLD-X program (Guerois R, Nielsen JE, Serrano L., J Mol Biol. 2002 Jul 5;320(2):369-87) which uses optimal energy functions to rank sequences according to their fitness for a given fold.
- 15 Such molecules identified herein specifically interfere at the ligand receptor family interface where apoptosis or autoimmune signalling pathways are triggered. A combined methodology that utilises the design approach outlined above in conjunction with such experimental techniques, is included as an aspect of the present invention.

- Molecules generated using the above methods may also be used to elucidate the mechanism of
- 20 action of  $\beta$  sheet multimeric cytokines. For example, although the crystal structures of TNF family members are known, little is known of the exact mechanism of binding and signal initiation by the ligand-receptor complex. Several TNF ligand family members, such as TRAIL, APRIL and RANKL, bind more than one receptor type which depending on receptor type may or may not trigger signal transduction pathways. Many questions therefore still exist with respect to molecular
  - 25 regulation of diseases such as cancer or autoimmune disease on the level of ligand-receptor complex formation and subsequent initiation of signal transduction. *In vitro* and *in vivo* studies aimed at the characterisation of this complex should add to a better understanding of the underlying (patho) physiological response and will aid in creating unique lead molecules. Use of these lead compounds will facilitate the elucidation of more complex basic questions in relation to protein-
  - 30 protein interaction, signal transduction pathways and bioactivity in *in vitro* and *in vivo* situations.

- In particular, protein or peptide mimetics generated may act as receptor agonists, antagonists, which may be engineered to have increased or decreased structural stability, receptor binding selectivity and/or bioactivity. In particular, such compounds have utility in the regulation of apoptosis. Members of the TNF ligand family induce signalling pathways that lead to apoptosis or
- 35 programmed cell death (PCD) through interaction with their cognate receptors. Ligand-bound

receptors transmit the signal across the membrane by bringing their cytoplasmic portions into close proximity, leading to the recruitment and activation of downstream effector proteins. Apoptosis, the mechanism whereby multicellular organisms dispose of superfluous or damaged cells in a controlled manner, is a process fundamental to the normal development and homeostasis of multicellular organisms. However, the impairment of apoptosis regulation is implicated in the pathogenesis of cancer and several chronic diseases, including acquired immunodeficiency syndrome (autoimmune disease and AIDS) and neurodegenerative disorders (eg Parkinsons). Common examples are chronic transplant dysfunction, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD) and asthma. Molecules that mediate reversal of imbalance in signal transduction could be effective therapeutics in diseases. Cell induced apoptosis is mediated chiefly by members of the TNF ligand family that interact with cognate receptors to trigger apoptosis. Soluble portions of these cytokines or their receptors, or mimetics thereof, are thus attractive candidates to be used as therapeutics for a variety of diseases related to apoptosis impairment.

In addition, a greater understanding of the role of TNF ligand family members may be achieved in controlling lymphocyte function, in order to identify novel targets for autoimmune therapy. Deregulated Activation-Induced Cell Death (AICD) may lead and contribute to autoimmunity. Impairment of AICD leads to accumulation of auto-reactive and chronically activated T cells. These cells can express various immune modulatory ligands, including APRIL and BAFF, which can alter B cell functions, causing autoantibody secretion and finally autoimmunity. The ligation of the TNF receptor family members may either lead to apoptosis through caspase-8/10 activation or, alternatively proinflammatory reactions, cell proliferation and differentiation through activation of NFkB. Activated T cells express a wide range of TNF ligand-receptor family members, all having different effects on lymphocyte fate. APRIL acts as a co-stimulator of T and B cells and enhances T cell survival in autoimmune disease. BAFF is essential for B cell T1 to T2 stage maturation, and thus, immunoglobulin secretion. RANKL initiates differentiation of osteoclast precursors that are responsible for bone desorption. In rheumatoid joints 40 % of the leukocytes are T cells, mainly CD4+. The proportion of B cells is only 1-5 %, although their contribution to chronic disease development is still great. Accumulation of these cells in inflamed joints leads to further lymphocyte activation and uncontrolled systemic immune responses. In RA, for example, one needs to target both hyper-plastic synovial cells and the immune cells accumulating in the joint capsule and also circulating in the body.

TNF family members are important immune regulators through promotion of proliferation and by participating in AICD of peripheral T cells. Inhibition of endogenous TRAIL function leads to impaired AICD, proliferation of autoreactive lymphocytes and synovial cells resulting in arthritic inflammation and joint tissue destruction (Song K. *et al.* J. Exp. Med., 2000; 191(7):1095). APRIL, on the other hand can act as a co-stimulator of T cells and is able to prolong T cell survival. By

dissecting the molecular pathway of T cell activation and the cell death induced by reactivation we can understand the exact role of TNF ligand family members in autoimmunity.

For example, studies of AICD human peripheral T cells may be isolated from the blood of healthy individuals. T cells can be activated by anti-CD3 and anti-CD28 antibodies, or  
 5 phytohaemagglutinin and maintained in the presence of various amounts of IL-2 and/or IL-15. AICD will then be induced at various days following activation by addition of anti-CD3 monoclonal antibodies. The potential of various TNF family members to induce AICD of CD4+ or CD8+ T cell populations at various times can then be tested by addition of agonistic/antagonistic ligands such as those described herein; these will compete with signalling.

- 10 Cell death in the CD4+ and CD8+ population can be tested by, for example, the 7-aminoactinomycin method (Szondy Z *et al.* 1998, J.Infectious. Dis.178:1288). In addition, the requirement for IL-2 in sensitising activated T cells to TRAIL-R and Fas-mediated death will be examined. Since IL-15 was shown to inhibit AICD, we will examine whether IL-15 interferes with  
 15 TNF receptor family expression of activated T cells and thus with sensitisation to AICD (Marks-Konczalik J. *et al.* PNAS 2000 97(21):11445-11450). Based on these findings a functional assay can be suggested to test possible deficiencies in various autoimmune patients. We will attempt to understand the function of APRIL in modulating T-cell survival. Using APRIL as a co-activator, together with anti-CD3, we will examine how it modulates TRAIL, FasL or TNF signalling, IL-2  
 20 secretion and in this way the influence on T cell survival. If TNF ligand family members or variants are shown to have an influence we will proceed to characterise these molecules in several forms of autoimmunity.

According to a further aspect of the invention, therefore, there is provided a  $\beta$  sheet multimeric cytokine whose sequence has been altered so as to generate a more stable cytokine than the wild-type, unaltered cytokine protein.

- 25 Multimeric cytokines included within the terms of the invention are all  $\beta$  sheet multimeric cytokines, as described above. Examples are presented in Table 6. Preferred multimeric cytokines according to the invention are members of the TNF ligand family (see Bodmer *et al.*, 2002. Trends Biochem. Sci. 27, 19). A preferred TNF ligand family member is the TRAIL protein.

- Preferably, such a  $\beta$  sheet multimeric cytokine is mutated in the soluble C-terminal portion of the  
 30 molecule. Examples of suitable residues for mutation are those at the following positions:

- a) a non-conserved residue at the surface of the monomer component of the multimeric cytokine (herein termed 'monomer' set);
- b) a non-conserved residue close to the interface between two of the monomer components of the multimeric cytokine (herein termed 'dimer' set);

c) for trimeric cytokines, a non-conserved residue along the central trimeric axis (herein termed 'trimer' set).

This list is not exhaustive – various miscellaneous mutations may also be made dependent on the particular cytokine, that do not fall into any of the three categories above. The identification of non-conserved residues is described above. Similarly, identification of residues that fall into the above classes a) to c) is also described above.

Preferably, a mutation in category a) falls in the external loop that connects that C and D anti-parallel beta strands of the cytokine (the CD loop), following the notation according to Eck (Eck *et al.*, J. Biol. Chem. 267, 2119-2122 (1992)). Preferred examples of such mutations in the TRAIL protein include positions E194 and I196. Equivalent mutations in other  $\beta$  sheet multimeric cytokines will be apparent to those of skill in the art. Preferably, mutations introduced at these residues are E194I and/or I196S.

In the TRAIL protein, when both these mutations are made, this has been found to result in a large improvement of free energy compared to wild-type TRAIL ( $\Delta\Delta G = -9.7 \text{ kcal mol}^{-1} \text{ monomer}^{-1}$ ). This high energy value is due to the fact that a trimer is being studied, in addition to the presence of significant van der Waals' clashes in the crystal structure ( $\sim 5 \text{ kcal mol}^{-1} \text{ monomer}^{-1}$ ), which are removed upon mutation. Preferably, mutations are made at both positions E194 and I196; more preferably, both the mutations E194I and I196S are made. The predicted increase in stability of this double mutant (herein termed M1) can be explained since Glu 194 is surrounded by hydrophobic groups (Trp 231, Phe 192, Ala 235) and the carboxyl group is uncompensated. The mutation Glu 194 to Ile rectifies this situation by replacing the charged residue for a medium-sized hydrophobic residue. Conversely, Ile 196 is surrounded by polar residues (Asn 202, Lys 233) and is very close to the backbone, resulting in probable van der Waals' clashes. Mutation to Ser avoids clashes and allows formation of a hydrogen bond to Asn 202, located in the opposite part of the CD loop. Both mutations improve polar solvation energy, in addition to ameliorating side chain and backbone entropy.

Preferably, a mutation in the dimer set may be made at one or more of the following positions: 125, 163, 185, 187, 232, 234, 237, 203, 205, 239, 241, 271 and 274. In the TRAIL protein, the residues at these positions are the following: H125, F163, Y185, Q187, S232, D234, Y237, D203, Q205, L239, S241, E271 and F274. The skilled reader will be able to identify equivalent positions in other  $\beta$  sheet multimeric cytokine proteins, for example, by multiple alignment or by structural alignment. Preferred mutations in this class include mutations at D203, Q205 and Y237. Preferably, mutations introduced at these positions are one or more of D203I, Q205M and Y237F. More preferably, two or all three of these mutations are made.

A mutant TRAIL protein comprising these three mutations is herein termed M2. The design of M2 leads to the creation of a hydrophobic cluster to stabilize the interaction between residues 203 and 205 (D strand) of one monomer, and residue 237 (F strand) of the adjacent monomer. Gln 205 and Tyr 237 together form an intermolecular hydrogen bond, and Asp 203 points to a gap in the monomer-monomer interface. Mutation to Ile (203), Met (205) and Phe (237) breaks the Q205-Y237 hydrogen bond, but facilitates the tight packing of these residues, improving van der Waals' interactions, hydrophobic and polar solvation energies of the entire TRAIL molecule, without a further increase of van der Waals' clashes.

Preferably, a mutation in the trimer set may be made at one or more of the following positions: 227, 230 and 240. In the TRAIL protein, the residues at these positions are the following: R227, C230 and Y240. The skilled reader will be able to identify equivalent positions in other  $\beta$  sheet multimeric cytokine proteins. A preferred mutation in this class is R227M. Also the combination of C230S and Y240 is preferred.

A mutant TRAIL protein comprising this mutation is herein termed M4. The Arg 227 residues of mutant M4 are located in strand E, equidistantly opposed in a central position along the longitudinal axis of the TRAIL trimer. The three arginines are surrounded by hydrophobic (Ile 242), polar (Ser 241, Ser 225) and aromatic (Tyr 240, Tyr 243) residues. These tyrosines direct the hydroxyl groups away from Arg 227, thus creating a rather hydrophobic cavity. The high concentration of positive charges is apparently not well compensated, since it forms only hydrogen bonds with the backbone (carbonyl groups of Ser 241). Thus, the mutation of these positions to Met could help to accommodate the hydrophobic environment, as well as to decrease the repulsion of monomers due to uncompensated positive charges.

Preferably, a mutation in the miscellaneous set may be made at one or more of the following positions: 123, 272, 225, 280, 163, 123 and 208. In the TRAIL protein, the residues at these positions are the following: A123, A272, S225, V280, F163, A123 and V208. The skilled reader will be able to identify equivalent positions in other  $\beta$  sheet multimeric cytokine proteins. A preferred mutation in this class is S225A.

A mutant TRAIL protein comprising this mutation is herein termed M3. Residue 225 of M3 (S225A), is located in strand E and is solvent exposed in the monomeric form. However, after trimerization, this position becomes buried in a small pocket, leaving the side chain of the hydrogen bond donor Ser uncompensated. After mutation to Ala, the energy of the model is better than wild-type TRAIL for both polar and hydrophobic solvation energies, in addition to side chain entropy.

A further preferred mutant  $\beta$  sheet multimeric cytokine is one which incorporates a combination of the mutations described above, such as 2, 3, 4, 5, 6, 7, 8, 9, 10 or more such mutations. One

example of such a mutant combines mutations at positions 194, 196 and 225. In the TRAIL protein, the residues at these positions are E194, I196 and S225. Preferably, the mutations introduced are E194I, I196S and S225A; a TRAIL mutant containing these three mutations has been engineered and is referred to herein as C1.

- 5 The above mutations may be introduced in the full length cytokine sequence. Preferably, however, the above mutations are introduced into soluble forms of  $\beta$  sheet multimeric cytokines. For the TRAIL protein, a preferred soluble template into which these mutations may be introduced comprises amino acids 114-281 of the full length TRAIL protein. However, as the skilled reader will appreciate, variations in this template will very likely retain the properties of this soluble form
- 10 and show biological activity if additional residues C terminal and/or N terminal of these boundaries in the polypeptide sequence are included. For example, an additional 1, 2, 3, 4, 5, 10, 20 or even 30 or more amino acid residues from the wild-type cytokine sequence, or from a homologous sequence, may be included at either or both the C terminal and/or N terminal of these boundaries, without prejudicing the ability of the polypeptide fragment to fold correctly and exhibit biological
- 15 activity. Similarly, truncated variants of this template in which one or a few amino acid residues (for example, 1, 2, 3, 4, 5, 10 or more) may be deleted at either or both the C terminus or the N terminus without prejudicing biological activity

The methods described above have been applied to a prototypic example, TRAIL, for purposes of illustration. It will be appreciated that this example is intended as illustrative and is not limiting in

- 20 any way. Novel mutants of TRAIL have been designed in order to increase the stability of the bioactive trimer. As will be evident from the Examples included herein, using this approach succeeded in extending the apparent thermal stability of the  $\beta$ -sheet protein by more than 5°C. This correlates with the preservation of overall structural characteristics as highlighted by the lasting bioactivity of these mutants as tested experimentally. For example, when measuring the residual
- 25 bioactivity of wild-type TRAIL and TRAIL mutants upon incubation at 73°C for 1 hour, it was shown that, while wild-type TRAIL was all but thermally inactivated after ~20 min, the TRAIL mutants M1, M2, M3 and C1, significantly, had an improved stability. Although not tested herein, it has been shown that in case of certain therapeutically interesting proteins, improvement of thermal stability can also be indicative of an improved *in vivo* half-life (Luo *et al.*, *Protein Sci.* 11,
- 30 1218-1226 (2002); Filikov *et al.*, *Protein Sci.* 11, 1452-1461 (2002)). Furthermore, the increase in thermal stability did not affect the biological activity of M1, M3 and C1. Significantly, it is shown herein that stabilisation of the CD loop in a single monomer resulted in stabilisation of the entire trimeric molecule.

As stated above, it would be desirable were it to be possible to alter the selectivity/specificity of cytokines for their cognate receptors. The inventors have now achieved, for the first time, the alteration of the receptor binding selectivity/specificity of a large multimeric protein structure using computational redesign. Automated computer algorithms have been used in combination with  
 5 hand-crafting and selection of pertinent residues to alter receptor binding selectivity of a multimeric all  $\beta$ -sheet protein, TRAIL.

Accordingly, this aspect of the invention provides a method for the alteration of the selectivity of a  $\beta$  sheet multimeric cytokine for a target receptor, the method comprising  
 identifying amino acids in the cytokine that are located in the receptor-binding interface as  
 10 candidates for mutation;

discarding residues interacting with amino acids that are conserved among receptors bound by the cytokine protein;

discarding residues interacting with the receptor backbone; and

substituting each of one or more residues in the cytokine protein for replacement residues that  
 15 include amino acid side-chain conformations that are predicted to fit into the binding interface with the target receptor so as to provide an increase in binding affinity of the cytokine protein for that target receptor.

As discussed above, alteration of selectivity for receptor is of significant interest in the cytokine field. For example, TNF ligand family members bind to receptors of the TNF receptor family, and  
 20 upon binding an intracellular signalling cascade is activated. Different cell subtypes have different profiles of TNF receptor family expression. Many TNF ligand family members can signal through more than one type of TNF receptor family member proteins, resulting in different biological activities, depending on the receptor and the expression profiles of these receptors on the cell surface. For a protein therapeutic/diagnostic it may be advantageous to selectively activate (or  
 25 inhibit) one of the receptors, for example to differentiate between a cell-proliferating activity and a cell-death inducing activity. Using the method of the invention described above, this is now possible even for large multimeric molecules. Furthermore, an improved selectivity/specificity would allow lower concentrations of a therapeutic variant to be administered than would be necessary with respect to wild-type cytokine.

30 Such selective variants of cytokines are advantageous for use as protein therapeutics or diagnostics, since they exhibit a relatively close resemblance to the wild-type structure and this reduces the risk of immunogenicity. They also have advantages when compared to agonistic or antagonistic antibodies. In contrast to antibodies, variants can be produced in *Escherichia coli* and the mode of signalling resembles the wild-type mode of signalling more closely.

According to the method of this aspect of the invention, selectivity for receptor is of primary importance. Accordingly, affinity for a receptor may be slightly compromised for improvements in selectivity/specificity.

- Using a method such as that described herein, novel mutants of the TRAIL protein have been
- 5 designed in order to shift selectivity/specificity towards its different membrane receptors (DR4 (TRAIL-R1), DR5 (TRAIL-R2), DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4)). As described above, having selective inducers of DR4 (TRAIL-R1) and DR5 (TRAIL-R2) signalling is of considerable interest, due to the different cross-linking requirements of both death receptors. Depending on the cross-linking the signalling pathway could induce the proliferative or the apoptic pathway.
- 10 Some residues important for binding and biological activity have been already identified in TRAIL by alanine-scanning mutagenesis (Hymowitz *et al.*, Biochemistry. 2000 Feb 1;39(4):633-40), but in this study, the inventors have focused not only in the identification of critical residues for selectivity, also have suggested the best amino acid substitution at these positions to get a maximum effect in selectivity. We show that some residues are critical for receptor binding and
- 15 selectivity; alanine-scanning mutagenesis could not identify these. The results also confirm that the choice of amino acid chosen for replacement is important.

This example acts as a prototypic example of how the method of the invention may be applied to a large multimeric  $\beta$  sheet protein. As the skilled reader will be aware, methods used in this study are also applicable to other multimeric cytokines, such as TNF family ligands.

- 20 For example, a recent significant publication has shown that TRAIL-R3 is upregulated by p53 in breast tumour cell through use of the genotoxic drug, doxorubicin (Ruiz de Almodóvar *et al.*, 2003, Nov 17, Manuscript M311243200). This implies that efficacy of wild-type TRAIL may be diminished in anti-tumour therapy since it also binds the decoy receptors (that do not initiate apoptosis). Therefore, variants of TRAIL, that have altered selectivity/specificity could be direct to
- 25 the pro-apoptotic receptors, DR4(TRAIL-R1) or DR5 (TRAIL-R2) and would have ultimately improved application in cancer treatment.

- Methods for identifying amino acids that are located in the receptor-binding interface are known in the art. Preferably, this is done through visualisation of the structure of the ligand protein, ideally in complexed form with receptor, using one or other of the many systems available. Such systems are
- 30 generally designed to import data describing a protein structure (such as a structure from the Protein Data Bank, the PDB) and convert this to a three-dimensional image. Images of protein structure allow intimate analysis of the structure of the protein to evaluate the positions of each residue in the protein structure, and an evaluation of which residues participate in interactions with other moieties, such as a receptor or monomer partner. Selected side chains are those in the protein
- 35 ligand that are physically close enough to be potentially interacting with receptor.



If no protein structure is available, it is likely that there will be structural information available for one or more homologous ligands and receptors, which allows the complexes to be built by Homology Modelling. This is particularly true in those cases in which the sequence homology is higher than 40% and insertions or deletions are not found in the binding region of ligand and receptor. For example, in the specific case of alteration of the selectivity of the TRAIL protein for DR5 (TRAIL-R2) or towards DR4 (TRAIL-R1), a crystal model of TRAIL in complex with the ectodomain of the DR5 (TRAIL-R2) receptor is available (PDB identifier 1DU3). Models of TRAIL complexed with the three other membrane receptors (DR4 (TRAIL-R1), DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4)) may be obtained using the "What If Homology Modeling web interface" (Vriend. *WHAT IF: A molecular modeling and drug design program*. *J. Mol. Graph.* (1990) 8, 52-56) (available at <http://www.cmbi.kun.nl/gv/servers/WIWWWI/>). Pdb files of TRAIL in complex with these three receptors can be generated by imposing their backbone atoms over the same atoms of the receptor DR5 (TRAIL-R2), using a program such as Swiss-PdbViewer v3.7b2 (Guex & Peitsch. *SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling*. *Electrophoresis* 18, 2714-2723 (1997)). Finally, template receptor DR5 (TRAIL-R2) is removed from the generated PDB file.

In a similar manner to the method of protein stabilisation described above, it is considered advantageous to use alignment information in order to focus the design on residues that do not interact with conserved residue positions in the target receptor. On occasion, however, altering conserved residues may also lead to changes in selectivity for the receptor. By conserved residue positions, is meant residues that are conserved between the different receptors that bind to the protein of interest. For example, the TNF ligand family TRAIL binds to four different membrane receptors (DR4 (TRAIL-R1), DR5 (TRAIL-R2), DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4)). Residues in the receptor binding interface that are conserved between the different receptors are likely to contribute to the binding of the ligand protein, meaning that their alteration would very likely disrupt important ligand-receptor interactions that are necessary for effective ligand-receptor binding. For the same reason, any residues that are predicted to interact with the receptor backbone are not considered suitable candidates for mutation.

As described above, identification of non-conserved residues can be done using any one of a number of systems known to the person of skill in the art, but preferably, computer-implemented alignment algorithms such as PSI-BLAST or ClustalW are preferred.

The combined approach of the method therefore employs family alignment information and a computational design algorithm. This reduces the sequence space search for every position in the protein being studied and decreases the computing time and power necessary for the methodology. This methodology allows rational design of the occurring interactions between the protein ligand

and its receptors. An overall visual inspection of the binding interface of ligand with the different receptors should also be carried out and, if necessary, some rotamers changed.

The method requires that each of one or more residues in the ligand protein are substituted for replacement residues that include amino acid side-chain conformations that are predicted to fit into the binding interface with the target receptor so as to provide an increase in binding affinity for that receptor. This step is preferably performed using a computer design algorithm such as PERLA, which performs inverse folding. Briefly, this algorithm decorates a fixed backbone structure with amino acid side chains from a rotamer library. PERLA thus performs a rotamer search looking for better side chain conformations, aiming to model the expected interactions of the protein ligand with its receptors. Relaxation of strain in the protein structure is achieved via the generation of subrotamers. Most terms of the scoring function are balanced with respect to a reference state, to simulate the denatured protein. The side chain conformers are all weighted using the mean-field theory and finally candidate sequences with modelled structures (PDB coordinates) are produced. Energy evaluation of the modelled structure must also be performed as part of this methodology, preferably using a program such as FOLD-X<sup>7</sup> or an improved version (such as that available at <http://fold-x.embl-heidelberg.de>). The force field module of FOLD-X evaluates the properties of the structure, such as its atomic contact map, the accessibility of its atoms and residues, the backbone dihedral angles, in addition to the H-bond network and electrostatic network of the protein. The contribution of water molecules making two or more H-bonds with the protein is also taken into account. FOLD-X then proceeds to calculate all force field components: polar and hydrophobic solvation energies, van der Waals' interactions, van der Waals' clashes, H-bond energies, electrostatics, and backbone and side chain entropies.

Using this program, all possible amino acid substitutions (preferably with the exception of Glycine, Proline, and Cysteine) are then introduced at the selected residue positions in the protein ligand in conformations (side chain rotamers) that are compatible with the rest of the structure. Glycine, Proline, and Cysteine are preferably omitted because Gly and Pro can influence the backbone conformation relatively more than other amino acids (Gly is more flexible, Pro less so). Also these residues have relatively large effects in the denatured state (Gly high entropy, Pro lower). Cys can also be difficult and is in an unpaired state that is generally unwanted in proteins, making them prone to aggregation and the like. Favourable mutations are then evaluated in terms of free energy (kcal mol<sup>-1</sup>), and unfavourable mutations (e.g. high Van der Waals' clashes) eliminated. An output of sequences and coordinates is then obtained and ranked in terms of free energy, for example, using the FOLD-X program. Some of these predictions can be discarded directly after theoretical energy calculations, without further experimental analysis. Others are progressed to mutagenesis studies. In this way, the method of this aspect of the invention substitutes one or more residues in the ligand protein substituted for replacement residues that include amino acid side-chain

conformations that are predicted to fit into the binding interface with the target receptor so as to provide an increase in binding affinity for that target receptor.

Favourable mutations may of course be combined and evaluated in terms of free energy (kcal mol<sup>-1</sup>). Unfavourable combinations (e.g. high Van der Waals' clashes) should be eliminated.

- 5 If necessary, outputs of sequences and co-ordinates may subsequent to the design process be reintroduced in the design algorithm for a further round or rounds of design. 2nd, 3<sup>rd</sup>, 4<sup>th</sup>, 5<sup>th</sup> or more rounds of design may be used.

Preferably, the method of this aspect of the invention may be applied to multimeric  $\beta$  sheet cytokines. Examples of such cytokines are presented in Table 6. Other examples will be known to

- 10 those of skill in the art.

Of particular interest for the application of the methodology of the invention are the  $\beta$  sheet multimeric cytokines that are members of the tumor necrosis factor ligand family. Ligands belonging to this family are involved in a wide range of biological activities, ranging from cell proliferation to apoptosis, and they share similar structural characteristics.

- 15 According to a further aspect of the invention, there is provided a  $\beta$  sheet multimeric cytokine whose sequence has been altered so as to alter its affinity for a particular target receptor.

Accordingly, one aspect of the invention relates to a cytokine that is mutated at one, two, three, four, five, six, seven or all eight of these positions. Preferably, such a cytokine is a member of the TNF ligand family. More preferably, such a cytokine is TRAIL.

- 20 Examples of suitable residues for mutation in TRAIL are those at the following positions:

131, 269, 130, 160, 218, 220, 149 and 155.

Equivalent residues (when crystal structural information is compared by eye or with use of molecular modelling) identified by those skilled in the art could be mutated in other  $\beta$  sheet multimeric cytokines, preference being for the cytokines of the TNF family.

- 25 Equivalent substitutions at the above positions, with a specific type of residue are preferred. For example, a preferred mutation at position 131 is to Arg. A preferred mutation at position 269 is to His. A preferred mutation at position 130 is to Glu. Preferred mutations at position 160 are Lys and Met. Preferred mutations at position 218 are to Arg, Tyr or Phe. Preferred mutations at position 220 are to Met or to His. Preferred mutations at position 149 are to Asp or to His. A preferred mutation  
30 at position 155 is to Met.

In the TRAIL protein, preferred mutations are G131R, D269H, R130E, G160K, D218R, G160M, D218Y, I220M, I220H, R149D, R149H, D218F and E155M. Particularly preferred TRAIL mutants

are G160M, D269H, D218Y, R130E and I220M. In particular, the G160M and D269H mutants are preferred as these are shown herein to have superior selectivity for the death receptor 5.

Some critical residues identified in TRAIL for receptor binding without distinction between DR4 and DR5 (TRAIL-R2) have been identified as Ile 220, Arg 149, Glu 155, Gly 160 and Asp 218.

5 The I220H and I22M mutants both highly increase DR4 binding, and have no effect on DR5 binding. The R149D mutant decreases binding to both the DR4 and DR5 receptors, whilst the R149H and D218R mutants have no effect on binding to either of these receptors. The E155 mutant highly decreases binding to both the DR4 and DR5 receptors; the D218F and D218Y mutants also decrease affinity, although to a lesser extent.

10 Also, it has been shown that different amino acid substitutions in the same position can have a different effect on receptor binding. Some positions, critical for receptor selectivity, due to a different decrease in receptor binding affinity between DR4 (TRAIL-R1) and DR5 (TRAIL-R2) have been identified as Arg 130, Gly 131 and Asp 269. The R130E and G131R mutants decrease binding to DR4 but only slightly decrease binding to DR5. In contrast, the D269H mutant highly  
15 decreases binding to DR4, but has no observable effect on binding to DR5.

The skilled reader will be able to identify equivalent positions in other  $\beta$  sheet multimeric cytokine proteins, for example, using multiple alignment programs or manual inspection of related sequences or structures.

20 Preferably, affinity for receptor is improved for DR4 (TRAIL-R1) or DR5 (TRAIL-R2) over the affinity for the decoy receptors DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4). More preferably still, affinity for DR5 (TRAIL-R2) receptor is improved over affinity for DR4 (TRAIL-R1).

The above mutations may be introduced in the full length cytokine sequence. Preferably, however, the above mutations are introduced into soluble forms of  $\beta$  sheet multimeric cytokines. For the TRAIL protein, a preferred soluble template into which these mutations may be introduced  
25 comprises amino acids 114-281. Equivalent soluble forms of other cytokines will be clear to the skilled reader. However, as the skilled reader will appreciate, variations in this template will very likely retain the properties of this soluble form and show biological activity if additional residues C terminal and/or N terminal of these boundaries in the polypeptide sequence are included. For example, an additional 1, 2, 3, 4, 5, 10, 20 or even 30 or more amino acid residues from the wild-  
30 type cytokine sequence, or from a homologous sequence, may be included at either or both the C terminal and/or N terminal of these boundaries, without prejudicing the ability of the polypeptide fragment to fold correctly and exhibit biological activity. Similarly, truncated variants of this template in which one or a few amino acid residues (for example, 1, 2, 3, 4, 5, 10 or more) may be deleted at either or both the C terminus or the N terminus without prejudicing biological activity.

The methods described above have been applied to a prototypic example, TRAIL, for purposes of illustration. It will be appreciated that this example is intended as illustrative and is not limiting in any way. Novel mutants of TRAIL have been designed in order to increase binding to the receptor DR4 (TRAIL-R1) relative to the binding to the receptor DR5 (TRAIL-R2). This

5 selectivity/specificity would allow lower concentrations of the variants to be administered, for example in the case of use as a therapeutic, than would be used with respect to wild-type TRAIL.

The skilled reader will appreciate that the methods described herein, for the stabilisation of a multimeric  $\beta$  sheet cytokine molecule, and for the alteration of selectivity of a multimeric  $\beta$  sheet cytokine molecule, may be combined.

10 In particular, combinations between the stability variants described above can be made, giving variants with enhanced stability and altered selectivity/specificity. Such combinations of stable and receptor selective/specific cytokine molecules are included as specific aspects of the present invention. Examples of such molecules include any one of the TRAIL M1, M2, M3 and C1 mutants, combined with one or more of the D269H, G160M, D218Y, R130E and I220M

15 selectivity/specificity mutants, which give variants with enhanced stability and altered selectivity/specificity.

Conventional experimental methodologies may be used to supplement the largely computational approach that is outlined above. For example, once amino acid substitutions have been identified, these substitutions should be produced experimentally using site-directed mutagenesis and then

20 tested for stability or selectivity/specificity and for retention of biological activity. Identified molecules can be further mutated using conventional techniques of molecular evolution, to develop more specific therapeutic lead molecules. In the case of molecular evolution, one particularly useful technology is phage display, which when coupled with an effective biopanning strategy, and when integrated with rational design methodologies, should result in rapid molecular evolution of

25 novel therapeutics.

The invention also provides purified nucleic acid molecules which encode a mutant  $\beta$  sheet cytokine as described above. Further aspects of the invention include vectors, such as expression vectors, that contain such nucleic acid molecules, along with host cells transformed with these vectors.

30 In an further aspect, the invention provides a  $\beta$  sheet multimeric cytokine whose sequence has been altered by a method according to any one of the aspects of the invention described above, or a nucleic acid molecule encoding such a molecule, or a vector containing a nucleic acid molecule as described, for use in the therapy or diagnosis of a disease in which cytokines are implicated. This aspect of the invention includes a method for the treatment of such a disease, comprising

35 administering to a patient, a cytokine, nucleic acid or vector as described above, in a

therapeutically-acceptable amount. Such molecules may also be used in diagnosis, for example, by assessing the level of expression or activity of a gene or protein (such as an over-expressed receptor) in tissue from said patient and comparing said level of expression or activity to a control level, wherein a level that is different to said control level is indicative of disease.

- 5 A further aspect of the invention may comprise a pharmaceutical composition comprising a mutant cytokine, nucleic acid or vector as described above, in conjunction with a pharmaceutically-acceptable carrier.

- A still further aspect of the invention may comprise transgenic or knockout non-human animals that have been transformed to express a mutant cytokine as described above. Such transgenic  
10 animals provide useful models for the study of disease and may also be used in screening regimes for the identification of compounds that are effective in the treatment or diagnosis of disease.

- Importantly, the generation of mutant cytokine molecules such as those described above allows for the design of screening methods capable of identifying compounds that are effective in the treatment and/or diagnosis of diseases in which these cytokines are implicated. The interacting  
15 domains of these molecules have an intrinsic propensity to initiate signalling pathways associated with the modulation of cancer and other chronic diseases, including autoimmune disease, and are starting points for drug design. Such screening methods are included as aspects of the present invention.

- Various aspects and embodiments of the present invention will now be described in more detail by  
20 way of example. It will be appreciated that modification of detail may be made without departing from the scope of the invention.

#### BRIEF DESCRIPTION OF DRAWINGS

- Figure 1. A) Side view of the TRAIL trimeric complex, showing the three monomers in red, blue and green. B) Top view of the same complex but viewed along the longitudinal axis, depicting the  
25 different sets used for design. Structure figures were generated using MOLMOL (Koradi *et al.*, *J. Mol. Graph.* 14, 51-32 (1996)).

Figure 2. Binding of wild-type TRAIL (●), M1(■) and M2 (○) to DR5 (TRAIL-R2) (···) and DR4 (TRAIL-R1) (—) receptors.

- Figure 3. Thermal denaturation profiles of wild-type TRAIL (●), M1(■), M2 (○), M3 (□) and C1  
30 (▲).

Figure 4. Stability of wild-type TRAIL (●), M1(■), M2 (○), M3 (□) and C1 (▲) at 73 °C for 60 min.

Figure 5. Remaining biological activity of wild-type TRAIL, M1, M3 and C1 (from left to right) upon incubation at 73 ° C during 60 min.

Figure 6. A) Comparison, between wild-type TRAIL and M1, of the local environment around residues 194 and 196. B) Comparison between wild-type TRAIL and M2. Backbones of the two adjacent monomers are in green and blue, respectively, and the backbone of the DR5 (TRAIL-R2) receptor is in grey. Hydrogen bond interactions are depicted in dashed green lines.

Figure 7. Receptor binding as a fraction of DR5 (TRAIL-R2) binding.

Figure 8. Receptor binding as a fraction of DR4 (TRAIL-R1) binding.

Figure 9. Cytotoxic potential of D269H – Annexin V staining.

10 Figure 10. Testing TRAIL receptor specific killing of D269H mutant – Annexin V staining.

Figure 11. DR5 (TRAIL-R2) selective killing by D269H - Annexin V staining.

Figure 12. D269H and TRAIL have comparable cytotoxic potential. A, cells treated with TRAIL and D269H for 2h; B cells treated for 3h (B). The graph shows a representative of 2 independent experiments.

15 Figure 13. Neutralisation of DR5, but not DR4 was able to block cell death induced by D269H.

## **EXAMPLES**

### **Example 1: Stable TRAIL proteins**

#### **Methods**

20 All reagents were of analytical grade unless specified otherwise. Isopropyl- $\beta$ -D-1-thiogalactoside (IPTG), ampicillin and dithiotreitol (DTT) were from Duchefa. Chromatographic columns and media were from Amersham Biosciences. Restriction enzymes used were purchased from New England Biolabs.

All other chemicals were from Sigma.

#### ***Computational design of mutants***

25 A detailed description of the protein design algorithm, PERLA, is available elsewhere (Lacroix,E. Protein design: a computer based approach, Ph.D.thesis. (U. Libre de Bruxelles,1999)) (<http://ProteinDesign.EMBL-Heidelberg.DE>) and its use has been previously described (see, for example, Ventura *et al.*, *Nat. Struct. Biol.* 9, 485-493 (2002)). In the case of oligomeric proteins like TRAIL, protein design with PERLA requires the following steps: Firstly, residues of a monomer  
30 that could establish specific interactions with the contiguous monomer must be identified and selected. Secondly, side chains that contact the residues to be mutated, must be identified to allow

side chain movements that are necessary to accommodate the new residues introduced by the algorithm. PERLA automatically selects these residues based on a geometrical approach that takes  $\text{Ca-Ca}$  distances and the angle between  $\text{Ca-C}\beta$  vectors into consideration. Thirdly, the algorithm places the amino acid repertoire at each position selected from a set of naturally occurring amino acids in a multiple sequence alignment of the TNF ligand family, and eliminates those side chain conformations and amino acids that are not compatible with the rest of the structure. Fourthly, all possible pair-wise interactions are explored to eliminate those combinations that are less favourable. Finally, an output of sequences and PDB coordinates corresponding to the best calculated solution (in terms of energy) is produced. The resultant PDB files containing the mutations were energy minimized using GROMOS 43B1 as implemented in Swiss-PdbViewer v3.7b2 (Guex, & Peitsch. *Electrophoresis* 18, 2714-2723 (1997))), and evaluated by FOLD-X (<http://fold-x.embl-heidelberg.de>). The final energies of the models are compared to the reference, wild-type TRAIL structure and expressed as  $\Delta\Delta G$  ( $\text{kcal mol}^{-1}$ ).

#### *Cloning and PCR*

cDNA corresponding to human soluble TRAIL (aa 114-281) was cloned in pET15B (Novagen) using *NcoI* and *BamHI* restriction sites. The N-terminal sequence encoding a His-tag and protease recognition site was therefore removed. Mutants were constructed by PCR using the Quick Change Method (Stratagene) or a modified megaprimer method (Picard *et al.*, *Nucleic Acids Res.* 22, 2587-2591 (1994)). The polymerase used was *Pfu* Turbo supplied by Stratagene. Purified mutagenic oligonucleotides were obtained from Invitrogen. Introduction of mutations was confirmed by DNA sequencing.

#### *Expression and purification of wild-type TRAIL and mutants*

The wild-type TRAIL and TRAIL mutant constructs were transformed to *Escherichia Coli* BL21 (DE3) (Invitrogen). Wild-type TRAIL and M1 were grown at a 5 l batch scale in a 7.5 l fermentor (Applicon) using 4 x LB medium, 1 % (w/v) glucose, 100  $\mu\text{g/ml}$  ampicillin and additional trace elements. The culture was grown to mid-log phase at 37 °C, 30 % oxygen saturation and subsequently induced with 1 mM IPTG.  $\text{ZnSO}_4$  was added at a concentration of 100  $\mu\text{M}$  to promote trimer formation. Temperature was lowered to 28 °C and the culture was grown until stationary phase. Other mutants were grown in shake flasks at a 1 l scale at 250 rpm, using a similar protocol. Protein expression was induced when the culture reached  $\text{OD}_{600}$  0.5 and induction was continued for 5 h. In this case, the medium used was 2 x LB without additional trace elements.

The isolated pellet was resuspended in 3 volumes extraction buffer (PBS pH 8, 10% (v/v) glycerol, 7 mM  $\beta$ -mercapto-ethanol). Cells were disrupted using sonication and extracts were clarified by centrifugation at 40,000 g. Subsequently, the supernatant was loaded on a nickel charged IMAC Sepharose fast-flow column and wild-type TRAIL and TRAIL mutants were purified as described



by Hymowitz (Hymowitz *et al.*, *Biochemistry* 39, 633-640 (2000)) with the following modifications: 10 % (v/v) glycerol and a minimal concentration of 100 mM NaCl were used in all buffers. This prevented aggregation during purification. After the IMAC fractionation step, 20  $\mu$ M ZnSO<sub>4</sub> and 5 mM of DTT (instead of  $\beta$ -mercapto-ethanol) was added in all buffers. Finally, a  
 5 gelfiltration step, using a Hiload Superdex 75 column, was included. Purified proteins were more than 98 % pure as determined using a colloidal coomassie brilliant blue stained SDS-PAGE gel. Purified protein solutions were flash frozen in liquid nitrogen and stored at -80 °C.

#### *CD Spectroscopy*

CD spectra were recorded on a Jasco J-715 CD spectrophotometer (Jasco Inc.) equipped with a  
 10 PFD350S Peltier temperature control unit (Jasco Inc.). Rectangular quartz cuvettes with a pathlength of 0.2 cm were used. Protein samples were dialyzed against PBS pH 7.3 and adjusted to a final concentration of 100  $\mu$ g/ml. Wavelength spectra were recorded between 250-205 nm using a 0.2 nm stepsize and 1 nm band-width at 25 °C. Temperature scans from 25-98 °C were performed at 222 nm with a scan rate of 40 °C/h. Thermal decay measurements were performed at 73 °C for 1  
 15 h at 222 nm.

#### *Bioactivity of TRAIL mutants in vitro*

Bioactivity of wild-type TRAIL and TRAIL mutants was determined using a viability assay according to the manufacturer's instructions (Celltiter Aqueous One, Promega). Colo205 human colon carcinoma cells (ATCC number CCL-222) were cultured in RPMI 1640 Glutamax  
 20 containing 10 % heat inactivated fetal calf serum and 100 units/ml Penicillin-Streptomycin. All reagents were supplied by Invitrogen. A concentration series of the wild-type TRAIL or TRAIL mutants was made in cell culture medium. 50  $\mu$ l of each dilution was added to a 96-well tissue culture micro plate (Greiner) and 100  $\mu$ l of cell suspension was added, to a final cell number of  $1 \times 10^4$  cells/well. Mixtures were incubated for 16 h at 37 °C under a humidified atmosphere  
 25 containing 5 % CO<sub>2</sub>. Subsequently, 20  $\mu$ l of MTS reagent was added. Cell viability was determined after 30 min incubation by measuring the absorption at 490 nm.

#### *Receptor binding*

Binding experiments were performed using a surface plasmon resonance-based biosensor Biacore 3000 (Biacore AB, Uppsala, Sweden), at 25 °C. Recombinant receptors were ordered from R&D  
 30 systems (R&D systems, Minneapolis, MN, USA). Immobilization of the receptors on the sensor surface of a Biacore CM5 sensor chip was performed following a standard amine coupling procedure according to the manufacturer's instructions. A reference surface was generated simultaneously under the same conditions but without receptor injection and used as a blank to correct for instrument and buffer artifacts. Purified wild-type TRAIL and TRAIL mutants were

injected in two-fold at a concentration of 2  $\mu\text{g/ml}$  and at a flow rate of 20  $\mu\text{l/min}$  flow rate. Binding of ligands to the receptors was monitored in real-time. The receptor/sensor surface was regenerated using 3 M sodium acetate pH 5.2 injections.

#### *Computer screening*

- 5 Novel mutants of TRAIL have been designed in order to increase the stability of the bioactive trimer. Predictions were based on the automated computer algorithm, PERLA, as described above. Briefly, the program performs strict inverse folding: a fixed backbone structure is decorated with amino acid side chains from a rotamer library. Relaxation of strain in the protein structure is achieved via the generation of subrotamers. Most terms of the scoring function are balanced with
- 10 respect to a reference state, to simulate the denatured protein. The side chain conformers are all weighted using the mean-field theory and finally candidate sequences with modelled structures (PDB coordinates) are produced. Energy evaluation of the modelled structures was carried-out by a modified version (Schymkowitz, J., Borg, J., Rousseau, F. & Serrano, L, "manuscript in preparation") of FOLD-X, available at (<http://fold-x.embl-heidelberg.de>). The force field module of
- 15 FOLD-X evaluates the properties of the structure, such as its atomic contact map, the accessibility of its atoms and residues, the backbone dihedral angles, in addition to the H-bond network and electrostatic network of the protein. The contribution of water molecules making two or more H-bonds with the protein is also taken into account. FOLD-X then proceeds to calculate all force field components: polar and hydrophobic solvation energies, van der Waals' interactions, van der Waals'
- 20 clashes', H-bond energies, electrostatics, and backbone and side chain entropies.

#### *Selection of the template sequence*

- The template selected was 1DU3 (Cha *et al.*, *J. Biol. Chem.* 275, 31171-31177 (2000)). The crystal structure at 2.2 Å resolution contains the trimeric structure of human TRAIL in complex with the ectodomain of the DR5 (TRAIL-R2) receptor. The TRAIL monomer lacks an external, flexible
- 25 loop (130-146), not involved in receptor binding or in monomer-monomer interaction. To complete the molecule, this loop was modelled using the structure of 1D4V (2.2 Å) (Mongkolsapaya *et al.*, *Nat. Struct. Biol.* 6, 1048-1053 (1999)), a monomeric TRAIL in complex with DR5 (TRAIL-R2) receptor, having the atomic coordinates of the loop. Finally, the TRAIL molecule was isolated by removing the receptor molecules from the PDB file.

#### 30 *Computational design of mutants*

The visual inspection of the isolated monomers, monomer-monomer interface and central core of TRAIL showed several residues as potential candidates for mutagenesis. The highly conserved hydrophobic residues were discarded from this list, as well as residues involved in receptor binding. These residues could not be mutated without disrupting interactions with the receptor. One

TRAIL variant (M2), however, that showed a significant predicted increase in stability but also contained residues involved in receptor interaction, was retained for subsequent experimental analysis.

The sequence space search for every position was simplified by checking the naturally occurring amino acids in a multiple sequence alignment of proteins belonging to the TNF ligand family, thus decreasing the computing time, and subsequently focusing on non-conserved residues. The use of protein rational design and force field algorithms (PERLA, FOLD-X) allowed the identification of a list of mutant sequences with potential relevance for TRAIL stability. Four sets of residues were selected for design (Figure 1b and Table 1): (1) non-conserved residues at the surface of the monomer ('monomer' set), (2) non-conserved residues near positions close to the interface between two monomers ('dimer' set), (3) non-conserved residues along the central trimeric axis ('trimer' set) and (4) a miscellaneous set ('misc. set'). The automated computer algorithm PERLA was applied as previously described (Angrand *et al.*, *Biomol. Eng* 18, 125-134 (2001)). Amino acid substitutions were introduced at the non conserved residue positions in conformations (side chain rotamers) compatible with the rest of the structure. Subsequently, favourable mutations were combined and evaluated in terms of free energy ( $\text{kcal mol}^{-1}$ ), and unfavourable combinations (e.g. high Van der Waals' clashes) were eliminated. An output of sequences and coordinates was produced and ranked in terms of free energy using FOLD-X and subsequently reintroduced in the design algorithm for a 2<sup>nd</sup>, 3<sup>rd</sup> or 4<sup>th</sup> round of design, if necessary. Table 1 summarizes the list of mutants assayed *in silico* for increased stability of TRAIL. Some of these predictions were discarded directly after theoretical energy calculations, without further experimental analysis.

## Results

### *Description of the tested mutations*

Predicted mutants were energy minimized and subsequently analyzed with FOLD-X. The energy values obtained were compared to that of the wild-type structure and used for discrimination of candidates. Mutants were selected based on an improvement in free energy relative to wild-type TRAIL (Table 2). In the monomeric set, M1 (E194I, I196S) was selected because of the large improvement of energy compared to wild-type TRAIL ( $\Delta\Delta G = -9.7 \text{ kcal mol}^{-1} \text{ monomer}^{-1}$ ). This high energy value is due to the fact that a trimer is being studied, in addition to the presence of significant van der Waals' clashes in the crystal structure ( $\sim 5 \text{ kcal mol}^{-1} \text{ monomer}^{-1}$ ), which are removed upon mutation. The mutations are located in the external loop connecting the C and D anti-parallel beta strands (CD loop), following the notation according to Eck (Eck *et al.*, *J. Biol. Chem.* 267, 2119-2122 (1992)). The predicted increase in stability of M1 can be explained since Glu 194 is surrounded by hydrophobic groups (Trp 231, Phe 192, Ala 235) and the carboxyl group is uncompensated. The mutation Glu 194 to Ile rectifies this situation by replacing the charged

residue for a medium sized hydrophobic residue. Conversely, Ile 196 is surrounded by polar residues (Asn 202, Lys 233) and is very close to the backbone, resulting in probable van der Waals' clashes. Mutation to Ser avoids clashes and allows formation of a hydrogen bond to Asn 202, located in the opposite part of the CD loop (Figure 6a). Both mutations improve polar solvation energy, in addition to ameliorating side chain and backbone entropy.

In the dimeric set (Table 2), the design of M2 (D203I, Q205M, Y237F) leads to the creation of a hydrophobic cluster to stabilize the interaction between residues 203 and 205 (D strand) of one monomer, and residue 237 (F strand) of the adjacent monomer. Gln 205 and Tyr 237 together form an intermolecular hydrogen bond, and Asp 203 points to a gap in the monomer-monomer interface.

Mutation to Ile (203), Met (205) and Phe (237) breaks the Q205-Y237 hydrogen bond, but facilitates the tight packing of these residues, improving van der Waals' interactions, hydrophobic and polar solvation energies of the entire TRAIL molecule, without a further increase of van der Waals' clashes (Figure 6b). Although FOLD-X predicted that the affinity of M2 for the DR5 (TRAIL-R2) receptor is lower ( $\Delta\Delta G_{\text{binding}} = 7.3 \text{ kcal mol}^{-1} \text{ monomer}^{-1}$ ) than for wild-type TRAIL, this mutant was retained as a control to evaluate the accuracy of the procedure.

Residue 225 of M3 (S225A), belonging to the 'Miscellaneous set', is located in strand E and is solvent exposed in the monomeric form. However, after trimerization, this position becomes buried in a small pocket, leaving the side chain of the hydrogen bond donor Ser uncompensated. After mutation to Ala, the energy of the model is better than wild-type TRAIL for both polar and hydrophobic solvation energies, in addition to side chain entropy.

The Arg 227 residues of the trimeric set mutant (M4) are located in strand E, equidistantly opposed in a central position along the longitudinal axis of the TRAIL trimer. The three arginines are surrounded by hydrophobic (Ile242), polar (Ser241, Ser225) and aromatic (Tyr 240, Tyr 243) residues. These tyrosines direct the hydroxyl groups away from Arg 227, thus creating a rather hydrophobic cavity. The high concentration of positive charges is apparently not well compensated, since it forms only hydrogen bonds with the backbone (carbonyl groups of Ser241). Thus, the mutation of these positions to Met could help to accommodate the hydrophobic environment, as well as to decrease the repulsion of monomers due to uncompensated positive charges.

#### *Mutagenesis and Purification of Mutants*

The highest ranking mutants M1 and M2 together with M3 and M4, were selected for further experimental analysis (Table 2). A mutant (C1) combining the mutations of M1 and M3 was also constructed. All the designed TRAIL mutants were expressed in *E. coli* and purified successfully with a protein yield of  $\sim 0.7\text{-}2 \text{ mg/l}$ . Far-UV CD wavelength spectra indicated that all mutants were properly folded with characteristics of a  $\beta$ -sheet containing protein, similar to that of wild-type TRAIL. Gel-filtration and dynamic light scattering measurements showed that all mutant protein

solutions contained a single molecule species, consistent with a trimeric oligomerization state. Analytical ultracentrifugation with wild-type TRAIL and M1 corroborated this finding (data not shown).

#### *In vitro bioactivity and binding of designed mutants*

- 5 Bioactivity of the TRAIL mutants was assessed *in vitro* using the Colo205 human colon cancer cell line with a MTT based viability assay. A reduction in viability was measured using increasing concentrations of wild-type TRAIL or TRAIL mutants relative to the control. While M1, M3 and C1 showed a bioactivity comparable to that of wild-type TRAIL ( $ED_{50} \sim 5$  ng/ml), M2 exhibited bioactivity of nearly one order of magnitude lower ( $ED_{50} \sim 50$  ng/ml). Real-time binding of wild-
- 10 type TRAIL and TRAIL mutants to the death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2) was assessed using surface plasmon resonance with a Biacore 3000 instrument. Sensograms of M1, M3 and C1 were identical to that of wild-type TRAIL. In contrast, M2 whilst showing a similar level of binding to both receptors, displayed an increased off-rate when compared to the wild-type TRAIL sensogram (Figure 2).

#### 15 *Thermal unfolding*

- The thermal unfolding of wild-type TRAIL and TRAIL mutants was monitored by measuring changes in molar ellipticity at 222 nm upon heating. Figure 3 shows the heat induced changes of wild-type TRAIL and TRAIL mutants. TRAIL shows an onset of unfolding at approximately 70 °C and has a transition midpoint of 77 °C. The TRAIL mutants show however, onset of unfolding at
- 20 increased temperatures and higher transition midpoints (Figure 3). For M1 the onset of unfolding was at approximately 76 °C and the transition midpoint was at 85 °C. M2 showed an onset of unfolding at approximately 74 °C. M3 gave intermediate values between those of wild-type TRAIL and M1, with an onset of unfolding of 73 °C and a transition midpoint of 80 °C. Mutant C1, representing the combined mutations of M1 and M3 showed values comparable to that of M1. The
  - 25 mutant belonging to the trimeric set (M4), however, showed an experimentally determined stability of approximately 3 °C less than wild-type TRAIL, and was therefore discontinued. The initial increase in molar ellipticity around 76 °C for M2 is due to an overall change of the far UV spectrum, reflecting a loss of structural properties of the starting material (data not shown). Upon cooling all protein solutions were turbid, indicating irreversible aggregation, therefore no
  - 30 thermodynamic parameters could be derived. Far and near UV wavelength CD scans at increasing temperatures confirmed the above findings (data not shown).

#### *Accelerated thermal stability study*

In order to test the stability of TRAIL and TRAIL mutants over time, an accelerated thermal stability measurement was performed. The temperature of 73 °C was chosen to measure effects on

stability within a 1 h timeframe. At this temperature wild-type TRAIL starts to unfold, while the mutants are still properly folded (Figure 3). Protein solutions with the same concentration as used in the thermal unfolding measurements were incubated at 73 ° C for 1 h and changes in molar ellipticity at 222 nm were measured (Figure 4). The ellipticity of wild-type TRAIL decreased from the onset, giving a half-life of approximately 13 min. The signal for the M1, M2 and C1 mutants remained essentially constant, indicating an increased thermal stability. M3 showed a half-life of approximately 24 min. These measurements, however, are not indicative of the bioactive trimeric structure of the TRAIL molecule, but of the secondary structure of the monomeric unit. To monitor a concomitant increase in biological activity at elevated temperatures of the mutants with unchanged biological activity (M1, M3 and C1), protein solutions with the same concentrations as used in the thermal unfolding measurements were incubated at 73 ° C and samples were taken at regular intervals for 1 h. Samples were subsequently diluted in tissue culture medium and added to Colo205 cells, resulting in a final concentration of 100 ng/ml. After overnight incubation the viability of the cells was measured using a MTT assay. Wild-type TRAIL showed decrease in bioactivity after 20 min of incubation, while M1 and C1 retained full bioactivity after incubation at 73 ° C for 1 h (Figure 5). M3 displayed an intermediate bioactivity between wild-type TRAIL and the other mutants. The increases in thermal stability of the mutants as measured with CD could therefore be correlated with a more stable biologically active trimeric molecule.

### Discussion

Others have previously applied computational engineering techniques to improve thermal stability of alpha-helical proteins or monomeric beta-sheet molecules. However, frequently, monomeric proteins of less than 100 amino acids were used as targets. To our knowledge, this report is the first example of computational redesign of a large trimeric all- $\beta$ -sheet protein towards a more thermal - stable variant. Significantly, it shows that the principles learned from design and engineering of small proteins can also be applied for large multimeric protein complexes.

The wild-type TRAIL (114-281) molecule has a relatively high thermal stability if compared to some members of the TNF ligand family. Human tumor necrosis factor alpha (TNF- $\alpha$ ), for example, has an apparent  $T_m$  of 65 °C as measured with circular dichroism (CD) (Narhi *et al.*, *Biochemistry* 35, 11447-11453 (1996)) and the CD40L receptor binding domain has an apparent  $T_m$  of 60 °C as measured with differential scanning calorimetry (DSC) (Morris *et al.*, *J. Biol. Chem.* 274, 418-423 (1999)). In parallel investigations, we can show using CD that RANKL however, is more thermal stable than TRAIL, with an apparent  $T_m$  of 5 °C higher than wild-type TRAIL, confirming another study (Willard *et al.*, *Protein Expr. Purif.* 20, 48-57 (2000)). In this study, we investigated the possibility of further increasing the thermal stability of TRAIL, as a model for all- $\beta$ -sheet proteins, through the use of computational engineering.

We succeeded in extending the apparent thermal stability of the  $\beta$ -sheet protein by more than 5 °C by using a combined approach, employing both TNF ligand family alignment information and an automated computational design algorithm. Due to the non-reversible nature of the unfolding reaction, the apparent  $T_m$  is not a perfect indication of an increase in stability. From a functional point of view, therefore, it also makes sense to study the time taken for the protein to denature at high temperature and to relate this to an effect on biological activity. The accelerated thermal stability study showed that the increase in thermal stability of the mutants as measured with CD spectroscopy (Figure 4) can be correlated with the preservation of overall structural characteristics as highlighted by the lasting bioactivity of M1 during the experimental timeframe (Figure 5). When measuring the residual bioactivity of wild-type TRAIL and TRAIL mutants upon incubation at 73 °C for 1 h, it was shown that, while wild-type TRAIL was all but thermally inactivated after ~20 min, the mutants, significantly, had an improved stability with respect to wild-type TRAIL (Figure 5). Thus measuring the stability of wild-type TRAIL and M1 at 73 °C is in this case indicative of an increased stability for M1 at more relevant temperatures, such as 37 °C or room temperature. Although not tested in this study, it has been shown that in case of certain therapeutically interesting proteins, improvement of thermal stability can also be indicative of an improved *in vivo* half-life (Luo *et al.*, *Protein Sci.* 11, 1218-1226 (2002); Filikov *et al.*, *Protein Sci.* 11, 1452-1461 (2002)). We are currently conducting studies to confirm this for our mutants.

It is advantageous to use alignment information in order to focus the design on non-conserved residue positions. The reason for this is that conserved residues are usually retained in a family for a good reason and it is probable that any mutation will decrease protein stability (Serrano *et al.*, *J. Mol. Biol.* 233, 305-312 (1993); Steipe *et al.*, *J. Mol. Biol.* 240, 188-192 (1994)). On the other hand, regions with high sequence variability are tolerant to mutation and it can be expected that variants that stabilize the protein can be found in these regions (Serrano *et al.*, *J. Mol. Biol.* 233, 305-312 (1993)). To accomplish our goal of redesigning a  $\beta$ -sheet protein, TRAIL, and to generate stable variants with the minimum number of mutations, the conserved residues forming the trimeric interface were therefore largely excluded from the prediction/optimization strategy. This resulted in an approach which focused mainly on improvement of the stability of the monomer (intra-chain stabilization; monomeric set) or improving monomer-monomer contacts (inter-chain stabilization; dimeric set). See Table 1.

M1, M2, M3 and C1 showed, in agreement with our predictions, an increase in thermal stability (Table 2; figure 3-5). Different basic principles were used in the M1, M2 and M3 designs. M1 shows an example of intra-chain stabilization. Stabilization of the flexible CD loop at the surface of each TRAIL monomer results in an increased stability of the entire trimer. This loop is not directly involved in receptor binding and is disordered in un-complexed wild-type TRAIL structures (Cha *et al.*, *Immunity.* 11, 253-261 (1999); Hymowitz *et al.*, *Biochemistry* 39, 633-640 (2000)), but

becomes ordered on binding to DR5 (TRAIL-R2) (Mongkolsapaya *et al.*, *Nat. Struct. Biol.* 6, 1048-1053 (1999); Hymowitz *et al.*, *Mol. Cell* 4, 563-571 (1999); Cha *et al.*, *J. Biol. Chem.* 275, 31171-31177 (2000)). M2, however, illustrates the optimization of the interactions between two adjacent monomers, i.e. inter-chain stabilization. M4 displays the stabilization of the trimeric molecule by removing a buried unsatisfied hydrogen bond donor. Contrary to our expectations, the combination mutant, C1 (M1 and M3 combined) did not result in significant additive thermal stability. This might be due to the effects of local unfolding around residue 194 and 196, which could be more dominant than the effects of unfolding around residue 225. Although the predicted free energy change relative to wild-type TRAIL ( $-9.1 \text{ kcal mol}^{-1} \text{ monomer}^{-1}$ ) is favourable for M4, the experimentally determined stability was approximately 3 °C less than wild-type TRAIL. This is probably due to the fact that, the three central arginines, in addition to the hydrogen bonds formed with the backbone, trap water in the central core of the trimer. Water bridges are thus formed to compensate the positive charges and this results in further stabilization of the trimer. The mutation Arg 227 Met is presumably less stable since the backbone's carbonyl groups are uncompensated and destabilize the trimer.

The increase in thermal stability did not affect the biological activity of M1, M3 and C1. M2 was more stable than wild-type TRAIL but the formation of an electrostatic interaction between Gln 205 and Arg 154 of the DR5 (TRAIL-R2) receptor was prevented (Figure 6b). This resulted in a subsequent 10-fold decrease in biological activity (50 ng/ml) when compared to wild-type TRAIL (5 ng/ml), as predicted by FOLD-X ( $\Delta\Delta G_{\text{binding}} = 7.3 \text{ kcal mol}^{-1} \text{ monomer}^{-1}$ ). Our findings confirmed an earlier study showing decreased bioactivity of alanine mutants at these positions (Hymowitz *et al.*, *Biochemistry* 39, 633-640 (2000)). Analysis of binding to the DR4 (TRAIL-R1) and DR5 (TRAIL-R2) receptors, using surface plasmon resonance, shows an increased off-rate for M2, indicating a lower affinity for both receptors, when compared to wild-type TRAIL and M1 (Figure 2). Since ligand-receptor binding sites are normally "high energy regions", the M2 mutations were expected to stabilize the TRAIL molecule. Thus, this could be regarded as an example of a possible increase in stability which is counterbalanced in evolution by loss of function.

Frequently, other computational redesign studies limited the screening for improvement of thermal stability to the core of the molecule (Malakauskas & Mayo, *Nat. Struct. Biol.* 5, 470-475 (1998); Luo *et al.*, *Protein Sci.* 11, 1218-1226 (2002); Filikov *et al.*, *Protein Sci.* 11, 1452-1461 (2002)). Here we show that computational redesign techniques can also involve inter-chain interfaces and surface residues of the molecule, to successfully stabilize the structure.

Performance of PERLA/FOLD-X was successful in the case of the intra-chain (monomer) set, the inter-chain (dimeric) set and the miscellaneous set. The experimental data corresponding to these designs showed all variants within these sets were more stable than wild-type TRAIL.



Significantly, we could show that stabilization of the CD loop in a single monomer resulted in stabilization of the entire trimeric molecule (Figure 6a).

Our studies have shown that computer redesign of a more thermal stable multimeric all  $\beta$ -sheet protein is achievable. Computational protein redesign is therefore a valuable addition to other protein engineering methodologies, such as directed evolution or experimental high throughput approaches, as a tool for the improvement of protein properties. Since the computational method used in our study is based on general physical principles, our findings can be further applied to design other TNF ligand family members with improved thermal stability.

#### **Example 2: TRAIL variants selective for the DR4 (TRAIL-R1) or DR5 (TRAIL-R2) receptor**

#### **10 Methods**

All reagents were of analytical grade unless specified otherwise. Isopropyl- $\beta$ -D-1-thiogalactoside (IPTG), ampicillin and dithiotreitol (DTT) were from Duchefa. Complete® protease inhibitor cocktail was purchased from Roche. Chromatographic columns and media were from Amersham Biosciences. Restriction enzymes used were purchased from New England Biolabs. All other chemicals were from Sigma.

#### *Computational design of mutants*

Computational design using the protein design algorithm, PERLA and FOLD-X has been described above. Similarly, the resultant PDB files containing the mutations were energy minimized using GROMOS 43B1 as implemented in Swiss-PdbViewer v3.7b2, and evaluated by FOLD-X (<http://fold-x.embl-heidelberg.de>). The final energies of interaction from the designs of TRAIL mutants interacting with its different receptors are compared to the reference, wild-type TRAIL in complex with its four membrane receptors and expressed as  $\Delta\Delta G$  (kcal mol<sup>-1</sup>).

#### *Computer screening*

Novel mutants of TRAIL have been designed in order to shift selectivity/specificity towards its different membrane receptors (DR4(TRAIL-R1), DR5(TRAIL-R2), DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4)). These receptors are described by Pan *et al.*, Science. 1997 Apr 4;276(5309):111-3 (DR4); Screaton *et al.*, Curr Biol. 1997 Sep 1;7(9):693-6 (DR5); Degli-Esposti *et al.*, J Exp Med. 1997 Oct 6;186(7):1165-70 (DcR1 (TRAIL-R3)) and Marsters *et al.*, Curr Biol. 1997 Dec 1;7(12):1003-6 (DcR2 (TRAIL-R4)).

Designs were based on the automated computer algorithm, PERLA, as described above. Briefly, this algorithm performs strict inverse folding: a fixed backbone structure is decorated with amino acid side chains from a rotamer library. Relaxation of strain in the protein structure is achieved via the generation of subrotamers. Most terms of the scoring function are balanced with respect to a

reference state, to simulate the denatured protein. The side chain conformers are all weighted using the mean-field theory and finally candidate sequences with modelled structures (PDB coordinates) are produced. Energy evaluation of the modelled structures was carried-out by a modified version (Schymkowitz, J., Borg, J., Rousseau, F. & Serrano, L, “manuscript in preparation”) of FOLD-X, 5 (available at <http://fold-x.embl-heidelberg.de>). The force field module of FOLD-X evaluates the properties of the structure, such as its atomic contact map, the accessibility of its atoms and residues, the backbone dihedral angles, in addition to the H-bond network and electrostatic network of the protein. The contribution of water molecules making two or more H-bonds with the protein is also taken into account. FOLD-X then proceeds to calculate all force field components: polar and 10 hydrophobic solvation energies, van der Waals’ interactions, van der Waals’ clashes, H-bond energies, electrostatics, and backbone and side chain entropies.

#### *Selection of the template sequence*

Template was selected from the Protein Data Bank, PDB identifier 1DU3. This is the crystal structure at 2.2 Å resolution of the trimeric structure of human TRAIL in complex with the 15 ectodomain of the DR5 (TRAIL-R2) receptor. In this structure TRAIL monomers lack an external, flexible loop (residues 130-146), not involved in receptor binding. To complete this template, this loop was modelled using the crystal structure of 1D4V (2.2 Å), a monomeric TRAIL in complex with DR5 (TRAIL-R2) receptor, which has the atomic coordinates of this loop.

#### *Modeling TRAIL non-crystallized receptors*

20 Models of the three other TRAIL membrane receptors (DR4 (TRAIL-R1), DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4)) were obtained using “What If Homology Modeling web interface” (available at <http://www.cmbi.kun.nl/gv/servers/WIWWWI/>). Afterwards, pdb files of TRAIL in complex with these three receptors were generated by imposing their backbone atoms over the same atoms of the receptor DR5 (TRAIL-R2), using Swiss-PdbViewer v3.7b2. Finally, template receptor DR5 25 (TRAIL-R2) was removed from the generated PDB file.

#### *Modeling interactions between TRAIL and modelled receptors*

Rational design of the occurring interactions between TRAIL and the three modelled receptors was carried out in the following way: First, receptors’ binding interface with TRAIL were studied looking for target amino acids for rotamer replacement. Selected side chains were the ones 30 physically close enough to TRAIL to be potentially interacting with it. Conserved residues with receptor DR5 (TRAIL-R2) were discarded from this rotamer replacement. Second, PERLA performed a rotamer search looking for better side chains conformations, aiming to model the expected interactions of TRAIL with these receptors. Finally, an overall visual inspection of the

binding interface of TRAIL with the different receptors was carried out and some rotamers were changed.

#### *Computational design of mutants*

Only TRAIL amino acids located in the receptor-binding interface were considered as potential candidates for *in silico* mutagenesis. Residues interacting either with conserved amino acids among the four different receptors or with receptor backbone were discarded from this list. The use of protein rational design and force field algorithms (PERLA, FOLD-X) allowed the identification of a list of mutant sequences with potential relevance for TRAIL selectivity/specificity.

The automated computer algorithm PERLA was applied as previously described. All possible amino acid substitutions (with the exception of Glycine, Proline, and Cysteine) were introduced at the previously selected residue positions in conformations (side chain rotamers) compatible with the rest of the structure. Subsequently, favourable mutations were evaluated in terms of free energy (kcal mol<sup>-1</sup>), and unfavourable mutations (e.g. high Van der Waals' clashes) were eliminated. An output of sequences and coordinates was obtained and ranked in terms of free energy using FOLD-X. Some of these predictions were discarded directly after theoretical energy calculations, without further experimental analysis.

#### *Cloning and PCR*

cDNA corresponding to human soluble TRAIL (aa 114-281) was cloned in pET15B (Novagen) using *NcoI* and *BamHI* restriction sites. The N-terminal sequence encoding a His-tag and protease recognition site was therefore removed. Mutants were constructed by PCR using the Quick Change Method (Stratagene) or a modified megaprimer method. The polymerase used was *Pfu* Turbo supplied by Stratagene. Purified mutagenic oligonucleotides were obtained from Invitrogen. Introduction of mutations was confirmed by DNA sequencing.

#### *Screening for selectivity mutants*

TRAIL mutant constructs were transformed to *Escherichia Coli* BL21 (DE3) (Invitrogen). Mutants and wild-type TRAIL were grown at a 10 ml scale, using a 2x LB medium. Cultures were grown to OD<sub>600</sub> 0.5 at 37 °C and 250 rpm, and protein expression was subsequently induced with 1 mM IPTG. ZnSO<sub>4</sub> was added at a concentration of 100 µM to promote trimer formation. Temperature was lowered to 28 °C and induction was continued for 5 h. Cells were harvested by centrifugation. Pellet was resuspended in extraction buffer (PBS pH 7.3, 10% (v/v) glycerol and Complete® protease inhibitor cocktail), in 25% of the original volume. Cells were disrupted using sonication and extracts were clarified by centrifugation at 20,000 g. TRAIL mutant protein expression was assessed using SDS-PAGE. Clarified extracts of mutants that were well expressed, were subsequently diluted 1:50 in HBS-EP buffer. These dilutions of the wild-type TRAIL and TRAIL

mutants were injected in two-fold, at a flow rate of 50  $\mu$ l/min on a Biacore 2000. A Biacore CM5 sensor chip coated with the TRAIL receptors DR4 (TRAIL-R1), DR5 (TRAIL-R2) and DcR1 (TRAIL-R3) and with RANK (receptor) as control surface, was used. Binding of ligands to the receptors was monitored in real-time. The receptor/sensor surface was regenerated using 3 M sodium acetate pH 5.2 injections. Ratios of binding for the different receptors were calculated relative to DR4 (TRAIL-R1) or DR5 (TRAIL-R2) binding, respectively. Mutants having different binding profiles compared to the binding profiles of wild-type TRAIL were chosen for subsequent analysis.

#### *Expression and purification of wild-type TRAIL and mutants*

- 10 The chosen mutants were grown in shake flasks at a 1 l scale at 250 rpm and 37 °C, using a 2x LB medium. Protein expression was induced with 1 mM IPTG when the culture reached OD<sub>600</sub> 0.5, ZnSO<sub>4</sub> was added at a concentration of 100  $\mu$ M. Temperature was lowered to 28 °C and induction was continued for 5 h. The isolated pellet was resuspended in 3 volumes extraction buffer (PBS pH 8, 10% (v/v) glycerol, 7 mM  $\beta$ -mercapto-ethanol). Cells were disrupted using sonication and
- 15 extracts were clarified by centrifugation at 40,000 g. Subsequently, the supernatant was loaded on a nickel charged IMAC Sepharose fast-flow column and wild-type TRAIL and TRAIL mutants were purified as described by Hymowitz (see above) with the following modifications: 10 % (v/v) glycerol and a minimal concentration of 100 mM NaCl were used in all buffers. This prevented aggregation during purification. After the IMAC fractionation step, 20  $\mu$ M ZnSO<sub>4</sub> and 5 mM of
- 20 DTT (instead of  $\beta$ -mercapto-ethanol) was added in all buffers. Finally, a gel filtration step, using a Hiload Superdex 75 column, was included. Purified proteins were more than 98 % pure as determined using a colloidal coomassie brilliant blue stained SDS-PAGE gel. Purified protein solutions were flash frozen in liquid nitrogen and stored at -80 °C.

#### *Screening for selectivity mutants*

- 25 Extracts of 16 expressing mutants were evaluated for binding to DR4 (TRAIL-R1), DR5 (TRAIL-R2) and DcR1 (TRAIL-R3) receptors using surface plasmon resonance with a Biacore 3000 instrument. Binding to murine RANK (receptor) was monitored as control as wild-type TRAIL does not bind to this receptor. Control extracts of BL21 (DE3) culture without an over-expression plasmid and of a BL21 (DE3) culture with plasmid over-expressing SH3 domain were also
- 30 injected. No binding was observed for these extracts. The ratio of DR4 (TRAIL-R1), DcR1 (TRAIL-R3) or RANK (receptor) binding with respect to DR5 (TRAIL-R2) receptor binding (Figure 7) and of DR5 (TRAIL-R2), DcR1 (TRAIL-R3) or RANK (receptor) binding with respect to DR4 (TRAIL-R1) receptor binding (figure 8), were calculated. The ratios values obtained for TRAIL selectivity mutants binding were compared to the ratios obtained for wild-type TRAIL

binding. Receptor binding curves were also visually inspected for alterations in on and off rates when compared to the on and off rates of wild-type TRAIL.

Two mutants, D269H and G160M, with a reduced binding to the DR4 (TRAIL-R1) and unchanged binding to the DR5 (TRAIL-R2) receptor ("selective" for DR5 (TRAIL-R2)) were chosen for further analysis. We have shown an increased off-rate of D269H w.r.t. DR4 but this does not imply that we have seen an increased binding for DR5. Our current data does imply that we have directed the binding of this mutant towards DR5 binding, hence it is more selective/specific for the DR5 receptor. Affinity can of course be improved after selectivity variants are chosen. I220M and E195R (not shown) were also elected, as they also showed a reduced binding to the DR4 (TRAIL-R1) and increased binding to the DR5 (TRAIL-R2) receptor. The effects, however, were smaller than that of the previous two mutants. D218Y was chosen for further analysis, as it showed a small preference for binding to the DR4 (TRAIL-R1) receptor, compared to wild-type TRAIL. R130E was chosen as it showed a small reduction in binding to the DcR1 (TRAIL-R3) receptor (less "selective" for DcR1 (TRAIL-R3)).

#### 15 *Determination of Receptor binding*

Mutants R130E, G160M, D218Y, I220M and D269H were purified. Binding of the purified mutants was assessed in real time using surface plasmon resonance on a Biacore 3000 with a sensor chip as described above. Mutants and purified wild-type TRAIL were injected in a concentration series of 17.3, 34.5, 69, 138 and 276 nM at a flow rate of 70  $\mu$ l/min. Measurements performed at 37 °C to allow increased  $k_{\text{off}}$  and dissociation was monitored for 20 min. Measured  $k_{\text{on}}$  and  $k_{\text{off}}$  rates were used to calculate apparent  $K_d$  values for the mutants for the respective receptors. A global fit procedure was used and a 1:1 Langmuir interaction model. A biphasic behavior was found for the  $k_{\text{on}}$  and  $k_{\text{off}}$ . The preliminary apparent  $K_d$  values were calculated and are shown in table 3.

#### *In vitro studies of the TRAIL mutants D269H*

#### 25 Experimental conditions

*Cell line and treatment:* Colo205 colon cancer cells were maintained in RPMI1640 medium, 10% FCS, 1% penicillin, 1% streptomycin in humidified incubator, 37 °C, in 5 %CO<sub>2</sub> environment. TRAIL receptor inhibitors (neutralising antibodies) were always added 1h before TRAIL addition. The Colo205 cells were seeded the day before the experiment at 10<sup>5</sup> cells/ml in 24 well plates, 1ml/well were treated with increasing concentration of antiDR4 and anti DR5 neutralising antibodies for 1h. 20ng/ml D269H was added to the cells and incubated for 2h and 30 minutes. After treatment, the cells were harvested by scraping them gently off the wells and spun down.

#### *Annexin V staining:*

Control or treated Colo205 cells were harvested and collected by centrifugation, washed once in Annexin V incubation buffer and resuspended in 400µl fresh incubation buffer. 1 µl Annexin V was added to the samples, incubated at room temperature for 10 minutes and measured immediately on a FACSCalibur Flow cytometer (Beckton Dickinson), results being expressed as % of annexin V positive cells.

*Caspase assay:* Colo205 cells were plated in 6 well plates at 200.000 cells/ml, 3ml/well on the day before the experiment. R2C16 (100ng/ml and 500ng/ml), antiDR4 (TRAIL-R1) and antiDR5 (TRAIL-R2) neutralizing antibodies (Alexis) (200ng/ml) were added into the culture medium 1h before adding TRAIL (10ng/ml). Cells were harvested for caspase activity assay after 2h treatment with TRAIL.

Cells were pelleted, washed twice in ice cold PBS, resuspended in 50ml PBS, 2x25ml cell suspension was snap frozen. Caspase enzyme activity was measured using fluorescently tagged DEVD-MCA (for caspase-3 and -7-like activity), or IETD-MCA (for caspase-8) tetrapeptides. The fluorescence intensity caused by the released MCA was measured kinetically in 25 cycles with 60 sec intervals. The enzyme activity was calculated as nmole MCA released per minute by 1 mg total protein.

*MTT assay:* Colo205 cells were seeded in 96 well plates at 200.000 cells/ml, 100µl/well. Each treatment was carried out in triplicates. After 24h treatment 500µg/ml MTT stain was added to the wells and was incubated at 37°C for 3h. The reaction was stopped and the formazan precipitate was dissolved by adding 100µl 20% SDS in 50% dimethylformamide.

### Results

For the analysis of the apoptosis inducing potential of D269H TRAIL sensitive Colo205 colon carcinoma cells were treated with increasing concentrations of TRAIL (aa 114-298) or D269H for 2 and 3 hours. Annexin V labelling of the apoptotic cells was used to monitor the level of cell death induced.

Our results (see Figures 9, 10 and 11) revealed that the two ligands have comparable death inducing potential in Colo205 cells. Thus, the designed mutations in D269H did not decrease its cytotoxic potential significantly (Figure 12).

In order to examine which TRAIL receptor is more involved in D269H induced death, 1 hour prior to D269H treatment of Colo205 cells, increasing amounts of neutralizing antiDR4 or antiDR5 antibodies were administered. The presence of the antiDR4 antibody failed to prevent death induced by D269H. On the other hand, already the lowest concentration (200ng/ml) of antiDR5 antibody almost completely prevented cell death (Figure 13). These results suggest that D269H induces cell death primarily through ligation of TRAIL receptor 2 (DR5). Similar studies on

different cell lines will be required to prove that this effect is not cell type specific and these are ongoing.

Table 1 Residues initially considered for design

Monomer Set	Dimer Set	Trimer Set	Misc. Set
E194 <sup>†</sup>	H125	R227 <sup>†</sup>	A123
I196 <sup>†</sup>	F163	C230	A272
	Y185	Y240	S225 <sup>†</sup>
	Q187		V280
	S232		F163
	D234		A123
	Y237 <sup>†</sup> (D203,Q205)		V208
	L239		
	S241		
	E271 <sup>†</sup>		
	F274		

<sup>†</sup> Used in subsequent rounds of design

Mutants in parenthesis were added in subsequent rounds as interaction partners



Table 2 Computational design results

	$\Delta\Delta G_{\text{stability}}^*$	$\Delta\Delta G_{\text{binding}}^{*\dagger}$	Set	Mutations
M1	-9.7	0.4	Monomer	E194I, I196S
M2	-4.0	7.3	Dimer	D203I, Q205M, Y237F
M3	-7.0	-0.5	Misc.	S225A
M4	-9.1	-1.2	Trimer	R227M
C1	-11.4	-0.9	Combination	M1+M3

\* Energy in kcal mol<sup>-1</sup>, calculated per monomer

$\dagger \Delta G_{\text{binding}} = \Delta G_{\text{complex}} - (\Sigma \Delta G_{\text{chain}})$ ;  $\Delta\Delta G_{\text{binding}} = \Delta G_{\text{binding}} \text{ mutant} - \Delta G_{\text{binding}} \text{ wild-type}$

Table 3. Apparent K<sub>d</sub> values for DR4 (TRAIL-R1) and DR5 (TRAIL-R2) receptors

	DR4(TRAIL-R1) (nM)	DR5(TRAIL-R2) (nM)
Wt TRAIL	0.6	0.4
G160M	0.4	0.5
D269H	0.6	< 0.4
D218Y	?	?
others	N.D.	N.D.

Table 4: Critical residues identified for receptor binding without distinction between DR4 and DR5.

<b>Mutant</b>	<b>Effect on DR4 binding</b>	<b>Effect on DR5 binding</b>
I220H	Highly decreases	Highly decreases
I220M	Highly decreases	Highly decreases
R149D	Decreases	Decreases
R149H	No observable effect	No observable effect
E155M	Highly decreases	Highly decreases
G160K	Highly decreases	Highly decreases
G160M	Highly decreases	Highly decreases
D218F	Decreases	Decreases
D218Y	Decreases	Decreases
D218R	No observable effect	No observable effect

5 Table 5: Critical residues identified for selectivity.

<b>Mutant</b>	<b>Effect on DR4 binding</b>	<b>Effect on DR5 binding</b>
R130E	Decreases	Slightly decreases
G131R	Decreases	Slightly decreases
D269H	Highly decreases	No observable effect

Table 6: The TNF ligand-receptor family and association with autoimmune disease

Ligands	Receptors	Function	Disease showing association
APRIL	TACI, BCMA and unknown	Probably co-stimulator of B and T cells	RA, SLE
4-1BBL (TNFSF9)	4-1BB (TNFSFR9)	T-cell costimulator/regulator	EAE, RA
BAFF (TNFSF13B/20)*	TACI, BCMA, BAFF-R	B cell survival/maturation, T cell costimulation	SLE, SS, RA
CD30L (TNFSF8)	CD30 (TNFSFR8)	Modulator of T cell function	SLE, RA, SS, autoimmune thyroid disease, primary biliary cirrhosis
CD40L (TNFSF5)*	CD40 (TNFSFR5)	B cell survival, stimulation and differentiation	SLE, SS, IBD, EAE
FasL (TNFSF6)	Fas (TNFSFR6), DcR3	Apoptosis	SLE, EAE, diabetes, autoimmune thyroid disease and autoimmune hepatitis
GITRL (TNFSF18)	GITR (TNFSFR18)	T-cell costimulator/regulator	unclear
LIGHT (TNFSF14)	LT $\beta$ -R, HVEM, DcR3 (TNFSFR6B)	T cell activation and thymocyte survival	Diabetes, possibly RA
LT $\alpha$ (TNFSF1) human	TNF-R1, TNF-R2, HVEM (TNFSFR3)	Inflammation	RA, SLE, IBD, MS, diabetes
LT $\alpha$ / $\beta$	LT $\beta$ -R, HVEM, DcR3 (TNFSFR6B)	Th1 responses, lymph node development, splenic architecture and organization	RA, SLE, IBD, MS, diabetes
OX40L (TNFSF4)	OX40 (TNFSFR4)	T-cell costimulator	EAE, RA, IBD
RANKL (TNFSF11)*	RANK (TNFSFR11A), OPG	Dendritic cell survival, osteoclast formation	RA
TNF (TNFSF2)*	TNF-R1 (TNFSFR1A), TNF-R2 (TNFSFR1B)	Inflammation, splenic organization	RA, SLE, IBD, MS, diabetes
TRAIL (TNFSF10)*	TRAIL-R1 (DR4, TNFSFR10A), TRAIL-R2 (DR5, TNFSFR10B), TRAIL-R3 (DcR1, TNFSFR10C), TRAIL-R4 (DcR3, TNFSFR10D), OPG (TNFSFR11B)	Induces tumour cell death Blocks T cell proliferation	Favorable in RA model Possible autoimmune thyroid disease; Possibly MS.
TWEAK	TWEAK-R	may contribute to macrophage homeostasis by mediating CD4 (+)T-cell killing of antigen-presenting macrophages; Induces proliferation in endothelial cells.	Brain inflammation; angiogenesis.
TWEPRIL	Possibly TACI, BCMA and unknown	Requires further elucidation	Requires further elucidation

MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren's syndrome; EAE, experimental autoimmune encephalomyelitis; IBD, inflammatory bowel disease.

## CLAIMS

1. A computer-implemented method for the stabilisation of a  $\beta$  sheet multimeric cytokine, comprising the step of:  
 mutating a residue in a monomer component of the multimeric cytokine protein so as to improve the free energy of the monomer or of the multimeric complex relative to the wild-type unmutated monomer component;  
 wherein said mutated residue is non-conserved between homologous members of the cytokine family.
2. A method according to claim 1, wherein the non-conserved residue that is mutated is at the surface of the monomer component of the multimeric cytokine protein.
3. A method according to claim 1, wherein the non-conserved residue that is mutated is near a position close to the interface between two monomer components of the cytokine protein.
4. A method according to claim 1, wherein in a trimeric cytokine protein, the non-conserved residue that is mutated is at a position along the central trimeric axis of the multimeric protein.
5. A method according to any one of claims 1-4, wherein more than one non-conserved residue is mutated.
6. A method according to any one of the preceding claims, wherein non-conserved residues are identified using a computer-implemented alignment algorithm.
7. A method according to claim 6, wherein in an alignment between the candidate for mutation and other members of the same protein family, a conserved residue is one that is shared between at least 50% of the family.
8. A method according to any one of the preceding claims, wherein a protein design algorithm is used to facilitate the identification of candidate residues for mutation.
9. A method according to claim 8, wherein said method performs an energy calculation involving the following steps:
  - a) identification of residues of a monomer that could establish specific interactions with the contiguous monomer;
  - b) identification of side chains that contact residues that are candidates for mutation;

- c) at each residue position is placed each amino acid in a repertoire selected from a set of naturally occurring amino acids in a multiple sequence alignment of members of the same protein family, and any side-chain conformations and amino acids that are not compatible with the rest of the structure are eliminated;
- 5 d) all possible pair-wise interactions are explored to eliminate those combinations that are not favourable.
10. A method according to claim 9, wherein said energy calculation is carried computationally, taking into account the properties of the structure, including its atomic contact map, the accessibility of its atoms and residues, the backbone dihedral angles, in  
10 addition to the H-bond network and electrostatic network of the protein, the contribution of water molecules making two or more H-bonds with the protein, polar and hydrophobic solvation energies, van der Waals' interactions, van der Waals' clashes, H-bond energies, electrostatics, and backbone and side chain entropies.
11. A method according to claim 10, wherein the method outputs a sequence and/or PDB  
15 coordinates corresponding to the best calculated solution.
12. A method according to claim 11, wherein the sequence and/or PDB co-ordinates including the mutations are energy-minimized and the final predicted energies are compared to the reference, wild-type structure in terms of  $\Delta\Delta G$  (kcal mol<sup>-1</sup>).
13. A  $\beta$  sheet multimeric cytokine whose sequence has been altered by a method according to  
20 any one of the preceding claims, so as to be more stable than the wild-type, unaltered cytokine protein.
14. A cytokine according to claim 13, which is a member of the TNF ligand family.
15. A cytokine according to claim 14, which is TRAIL.
16. A cytokine according to claim 15, which is mutated in the soluble C-terminal portion of  
25 the molecule.
17. A cytokine according to claim 15 or 16, which is mutated at one or more of the following positions:
- a) a non-conserved residue at the surface of the monomer component of the multimeric cytokine;
- 30 b) a non-conserved residue close to the interface between two of the monomer components of the multimeric cytokine;
- c) for trimeric cytokines, a non-conserved residue along the central trimeric axis;


- d) a miscellaneous residue whose mutation is energetically favourable.
18. A cytokine according to claim 17, which is mutated in the external loop that connects that C and D anti-parallel beta strands (the CD loop), following the notation according to Eck (Eck et al., J. Biol. Chem. 267, 2119-2122 (1992)).
  - 5 19. A cytokine according to claim 17 part a), which is mutated at one or both positions 194 and 196.
  20. A cytokine according to claim 19, which is a TRAIL mutant containing the mutations E194I and/or I196S.
  21. A cytokine according to claim 17 part b), which is mutated at one or more of the positions  
10 125, 163, 185, 187, 232, 234, 237, 203, 205, 239, 241, 271, 274.
  22. A cytokine according to claim 21, which is a TRAIL mutant containing one or more of the mutations D203I, Q205M and Y237F.
  23. A cytokine according to claim 17 part c), which is mutated at one or more of positions 227, 230 and 240.
  - 15 24. A cytokine according to claim 23, which is a TRAIL mutant containing the mutation R227M.
  25. A cytokine according to claim 23, which is a TRAIL mutant containing the mutation C230S and Y240F.
  26. A cytokine according to claim 17 part d), which is mutated at one or more of the positions  
20 123, 272, 225, 280, 163, 123 and 208.
  27. A cytokine according to claim 25, which is a TRAIL mutant containing the mutation S225A.
  28. A cytokine which is mutated at more than one position as listed in claim 17, parts a) to d).
  29. A cytokine according to claim 27, which is a TRAIL mutant containing the mutations  
25 E194I, I196S and S225A.
  30. A cytokine according to any one of claims 13-28, wherein the described mutations are introduced into a soluble form of the cytokine.
  31. A cytokine according to claim 29, which is a TRAIL mutant comprising residues 114-281.
  - 30 32. A method for the alteration of the selectivity of a  $\beta$  sheet multimeric cytokine for a target receptor, the method comprising

- a) identifying amino acids in the cytokine that are located in the receptor-binding interface as candidates for mutation;
  - b) discarding residues interacting with amino acids that are conserved among receptors bound by the cytokine protein;
  - 5 c) discarding residues interacting with the receptor backbone; and
  - d) substituting each of one or more residues in the cytokine protein for replacement residues that include amino acid side-chain conformations that are predicted to fit into the binding interface with the target receptor so as to provide an increase in binding affinity and selectivity/specificity of the cytokine protein for that target receptor.
- 10 33. A  $\beta$  sheet multimeric cytokine whose sequence has been altered by a method according to claim 31 so as to alter its affinity for a particular target receptor.
34. A cytokine according to claim 32, which is mutated at one or more of the positions 131, 269, 130, 160, 218, 220, 149 and 155 in the cytokine.
35. A cytokine according to claim 32 or 33, which is a member of the TNF ligand family.
- 15 36. A cytokine according to claim 34, which is TRAIL.
37. A cytokine according to claim 35, which has superior selectivity for the DR5 (TRAIL-R2) or DR4 (TRAIL-R1) over the decoy receptors DcR1 (TRAIL-R3) and DcR2 (TRAIL-R4).
38. A cytokine according to claim 35, which has superior selectivity for the death receptor 5 (TRAIL-R2) over selectivity for the death receptor 4 (TRAIL-R1)
- 20 39. A cytokine according to claim 37, which contains one or more of the mutations G131R, D269H, R130E, G160K, D218R, G160M, D218Y, I220M, I220H, R149D, R149H, D218F and E155M.
40. A cytokine according to claim 38, which contains the mutations G160M or D269H.





A



B




Figure 1






Figure 2






Figure 3






Figure 4








Figure 5






Figure 6



# Receptor binding as a fraction of DR5 binding




Figure 7



# Receptor binding as a fraction of DR4 binding




Figure 8





**Figure 9**






Figure 10









Figure 11







A



B

Figure 12.








Figure 13.

PCT/IB2004/004335

